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ABSTRACT 
Marijuana, Methamphetamine, and Oxycodone: A multileve  approach to understanding drug 
effects 
Diana R. Keith 
 
Drug use and abuse remains an important public health problem in the United States. In 
particular, there has been considerable recent concern regarding the illicit use of marijuana, 
methamphetamine, and prescription pain relievers. However, several important gaps remain in 
our knowledge of these drugs. The current studies aim to address three of these gaps. Further, the 
present studies utilized a translational, multileve approach in order to better understand 
substance use as a whole. First, although there hav been a number of studies examining 
marijuana use in college students, there is a lack of information regarding the consequences of 
marijuana and alcohol co-use, as well as the relationship between marijuana use and mental 
health and stress. Study 1 examined the relationship between frequency of marijuana use and 
other substance use, binge drinking, negative consequences associated with drinking, mental 
health problems, and stress. Results show that students who reported more frequent marijuana 
use were more likely to use all other substances, binge drink, and have drinking-related 
encounters with the police. Frequency of use was also related to diagnosis and/or treatment for 
major depression and substance use disorders. On the other hand, any marijuana use was 
associated with greater likelihood of experiencing a number of negative consequences from 
drinking, and diagnosis or treatment for anxiety disorders. Marijuana was not related to stress. 
This data contributes to the field by indicating that marijuana use is indeed related to mental 
health among this population. This has important implications for university administrators and 
health professionals. Study 2 was the first empirical investigation of the acute effects of 
 
marijuana during simulated night shift work in marijuana users. Night shift workers are 
particularly susceptible to performance impairments and often use drugs in order to manage their 
sleep-wake cycles. The results indicated that smoked marijuana attenuated performance and 
mood disruptions during simulated night shift work. This data furthers the database by indicating 
that marijuana has cognitive-enhancing effects under certain conditions. Additional research will 
be needed in order to determine whether these effects were caused by circadian modulation of 
the stimulant-related effects of marijuana, or by residual effects on improved sleep. Another 
important gap addressed by the present studies is the dearth of empirical information regarding 
the effects of methamphetamine when combined with oxyc done. Study 3 addressed this gap by 
beginning a systematic investigation of this drug combination utilizing a pre-clinical model with 
a wide range of cognitive and behavioral measures. R ults indicated that the drug combination 
produced stronger effects than either drug alone, although this was observed in a limited number 
of measures. These data importantly provide the first empirical determination of the effects of 
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Chapter 1: General Introduction 
Illicit drug use in the United States has been slowly increasing for the past 15 years. In 
1999, 6.3 percent of Americans aged 12 years and older reported illicit drug use in the past 30 
days (referred to as “current use”: SAMSHA 2002). By 2012, this number had risen to 9.2 
percent (SAMSHA 2013a). In particular, there has been considerable recent concern regarding 
the illicit use of marijuana, methamphetamine, and prescription pain relievers. 
 
1.1 Marijuana 
Federally, marijuana is classified as a Schedule I drug, making it one of the most 
restricted drugs in the country. Schedule I drugs are s id to have no currently accepted medical 
use, high potential for abuse, and lack accepted safety for use even under medical supervision.  
Thus, under federal law, it is illegal to manufacture, distribute, dispense, or possess marijuana. 
Despite the federal classification, 20 states and the District of Columbia have enacted laws 
protecting the medical use of marijuana. A growing number of other states are considering 
measures that will also legalize medical marijuana. Further, 16 states have made possession of 
marijuana a civil violation rather than a criminal one. Finally, Colorado and Washington have 
legalized marijuana for recreational use. Some have predicted that recent legislative move will 
increase marijuana availability and use. And, as a result, concern has been raised about 
marijuana-related negative consequences, including performance disruptions, addiction (defined 
by the DSM V as meeting two or more criteria for sub tance use disorder) and mental illness. 







1.1.1 Illicit marijuana use in the United States  
Marijuana is the most commonly used illicit drug in the world. In the U.S., approximately 
18.9 million (7.2 percent of the population) are current illicit marijuana users (SAMSHA 2013a). 
Between 2007 and 2012, the rate of past 30 day marijuana use increased from 5.8 to 7.3 percent; 
daily or almost daily use increased from 2.1% to 2.9% of the population (SAMSHA 2013a). 
Marijuana also represents the illicit drug with thelargest number of persons classified with past 
year abuse or dependence (4.3 million or 1.7% of the population; SAMSHA 2013a).  In 2011, 
approximately 333,000 Americans sought treatment for their marijuana use, accounting for 18 
percent of all treatment admissions (SAMSHA 2013b).  Marijuana was the third most commonly 
reported primary substance at treatment admission, after alcohol (39%), and opiates (25%; 
SAMSHA 2013b). Data from the Drug Abuse Warning Network (DAWN) show that there were 
approximately 455,000 emergency visits related to marijuana either alone or in combination with 
other illicit drugs, representing 36 percent of all illicit drug-related emergency department visits 
(SAMSHA 2013c). It is important to note that high rates of marijuana-related mentions in the 
emergency department data are not surprising given that it is the most widely used illicit drug. 
Also, one should be mindful that most emergency department drug mentions are due to multiple 
drugs rather than a single drug. Nonetheless, the she r number of current marijuana users 
suggests that there will be some negative consequences that warrant public health attention.   
One such concern is marijuana use by young people. Ind ed, marijuana use- as well as 
use of other recreational drugs- is most common among those between the ages of 18-25 years.  
The number of young people using marijuana has increased in the past several years. For 
example, in 2008, the percentage of young adults reporting current marijuana use was 16.6; by 





While many young people may not experience any negative effects from marijuana use, 
some studies estimate that 1 in 11 people who ever use marijuana will become dependent 
(Anthony 1994). Persistent, daily smoking of marijuana impairs lung function (Tashkin 2001) 
and withdrawal is associated with a number of deleterious effects such as disrupted sleep, 
decreased appetite, and negative mood states such a irritability, depression, and anger (Budney 
et al. 2007).  
Young adults also show the highest rates of drug abuse and dependence. In 2007, 21.1 
percent of persons aged 18 to 25 were classified as needing treatment for alcohol or illicit 
substance use (SAMSHA 2009). Only 7 percent of those received treatment (SAMSHA 2009). 
Most young adults in need of treatment did not recognize that they had drug-related problems. 
Further, drug use by young adults has also been associ ted with a number of mental health 
problems. It is important to note that the relationship between mental health and substance use is 
bidirectional; substance use may intensify pre-existing mental health problems, and mental 
health problems may worsen substance abuse. The complex interaction between the two makes 
the association difficult to study. 
Taken together, this data indicates that young adults are particularly vulnerable 
population to marijuana-related negative consequences. The transition from adolescence to 
adulthood is a key life change that brings increased risk for drug use and mental health problems. 
To date, there has been little research examining the relationship between marijuana use and 
mental health in college students, a population that is more likely to engage in marijuana use 
(past year use: college: 34.9 percent, non-college: 32.7 percent) and, as a result, might be at great 
risk for mental health problems. Therefore, the first aim of this project was to investigate the 





utilized a convenience sample of undergraduates enroll d at a university in the Northeast. 
Participants completed an online survey assessing drug use behaviors, mental health, and 
demographics. Specifically, we examined the relationships between marijuana use and other 
illicit drug use, binge drinking, negative consequenc s from drinking, mental health problems 
and perceived stress. This data will inform the datab se regarding marijuana use and mental 
health among college students. 
 
1.1.2 Acute effects of marijuana 
 While the above data will provide important information about mental health correlates 
and reported marijuana use, they do not provide a msure of marijuana’s direct (or acute) 
effects. Study 2 will investigate the acute effects of marijuana.  It is well known that marijuana 
increases heart rate and euphoria, with peak effects occurring within 10 minutes after smoking 
and all effects diminishing within 2 hours (Hart et al. 2001; 2005). The drug also has been shown 
to produce negative effects on cognitive functioning, but the extent of these effects are dependent 
upon a variety factors, including the marijuana use hi tory of the user.   
 
1.1.3 Factors influencing the acute effects of mariju na 
 A critical factor that modulates marijuana-related effects is marijuana use history. For 
example, during intoxication, infrequent users have be n shown to exhibit slower reaction time 
and disruptions in short-term memory and inhibitory control (e.g., Fant et al. 1998; Curran et al. 
2002; D’Souza et al. 2004). The performance of frequent marijuana smokers, on the other hand, 
is less affected during intoxication (e.g., Ward et al. 1997; Haney et al. 1999; Hart et al. 2001, 





that marijuana functions as a nootropic (i.e., cognitive-enhancer) for some frequent smokers 
(e.g., Weil et al. 1968; Schafer & Brown 1991).  
Environment factors, such as time-of-day, are also known to powerfully influence drug 
effects, although there are virtually no data assessing the influence of time-of-day on marijuana-
related effects. Keith et al. (2013) assessed the influence of time-of-day on methamphetamine-
related effects in mice and found that the drug produce greater intake and motor activity effects 
when administered during the early sleep period versus the late sleep period. These data show 
drug effects are altered as a function of time of day. 
Rotating shift work, particularly night-shift work, requires individuals to alter their 
normal sleep-wake cycles and perform during times when their circadian rhythms make them 
least alert (for a review, see Arendt 2010). Hence, shift-workers have higher rates of workplace-
related injuries (Dembe et al. 2008), performance decrements (Fido and Ghali 2008) and reduced 
productivity (Akerstedt 1998). These workers may be more susceptible to drug misuse due to 
shift workers seeking strategies, including pharmacological ones, to offset shift work-related 
disruptions. There are no data investigating marijuna-associated effects on cognitive 
performance and mood during shift work. Thus, the second aim was to examine the effects of 
smoked marijuana on the daytime and night-time performance during shift work in current 
marijuana smokers. 
 One difficulty in studying the effects of drugs in humans is creating a balance between a 
controlled laboratory environment and an experience that mimics the “real world.” Human 
laboratory studies must control as many potentially confounding variables as much as possible, 
while creating an environment that does not make participants uncomfortable. To this end, Hart 





Residential Laboratory at the New York Psychiatric Institute (NYSPI). This laboratory models a 
4-bedroom apartment and is located within the hospital, allowing for continuous observation of 
behavior. Each participant resides in a private bedroom, equipped with a bed, desk, Macintosh 
computer system, refrigerator, microwave, toaster, food preparation area, and a barcode scanner 
for food requesting and reporting. The laboratory also includes a common area, in which 
participants were free to engage in social and recreational activities, such as watching videotaped 
films, playing video games and board games, reading, a d exercising. In Study 2, participants 
lived in this laboratory for three weeks while shifting between working 3 days on a day shift 
(0830-1730h) and 3 days on a night shift (0030-0930h), with shift condition switching several 
times during the study. This method allows for a naturalistic setting that mimics night-shift work 
conditions experienced in the natural ecology. Study 2 examined the effect of marijuana on 
cognition and mood during simulated shift work. We hypothesized that marijuana would 




1.2.1 Illicit methamphetamine use in the United States 
Methamphetamine use has also generated a considerable amount of concern, despite 
comparatively low levels of use. In 2012, the number of past 30 day methamphetamine users was 
approximately 440,000, or 0.2 percent of the population (SAMSHA 2013a). In 2011, 
approximately 102,000 people sought treatment for methamphetamine dependence (SAMSHA 





drug-related emergency visits in 2011 were related to methamphetamine alone or in combination 
with other drugs.  
Longitudinal data indicates that methamphetamine use has been declining in recent years. 
Between 2006 and 2012, the number of current methamp etamine users decreased by almost half 
(731,000 to 440,000; SAMSHA 2013a). Between 2004 and 2012, the number of past year 
initiates of methamphetamine similarly decreased by more than 50 percent (318,000 to 133,000; 
SAMSHA 2013a). Nonetheless, methamphetamine use and production is still perceived as 
extensive. 
It is important to note that when compared to mariju na users, a greater percentage of 
methamphetamine users experience drug-related problems, despite overall lower levels of use. 
Indeed, there are a number of potential negative consequences associated with methamphetamine 
abuse and dependence. For example, large doses of the drug can cause paranoia that mimics 
psychosis (Grelotti et al. 2010) and hypertensive crisis leading to stroke (Ho et al. 2009). 
However, to date, there is still a paucity of research on the consequences of this drug.  
 
 
1.2.2 Acute effects of methamphetamine 
Briefly, it is well established that intranasal methamphetamine increases cardiovascular 
measures such as heart rate and blood pressure, with peak effects occurring approximately 10 
minutes after administration and lasting for 4 hours (Hart et al. 2008). Methamphetamine 
produces prototypical stimulant effects such as increased ratings of “high” and “stimulated,” and 
decreased ratings of “tired” and “hungry.” Similar to cardiovascular measures, these effects peak 





functioning in a few cognitive domains, such as vigilance and visuospatial processing. Decreased 
food intake and sleep are also commonly observed following methamphetamine administration 
(Comer et al. 2001). Study 3 will investigate the direct (or acute) effects of methamphetamine 
when combined with a narcotic pain-reliever. 
 
1.3 Nonmedical use of pain relievers 
 
1.3.1 Illicit pain reliever use in the United States 
In addition to marijuana and methamphetamine, there as been considerable concern 
regarding the nonmedical use of pain relievers. Second only to marijuana, in 2012 there were 4.9 
million current users of nonmedical pain relievers (SAMSHA 2013a). Approximately 187,000 
people sought treatment for non-heroin opiate dependence, a full 10% of all treatment 
admissions in 2011 (SAMSHA 2013b). In particular, there has been concern regarding the use of 
oxycodone. This drug is used to manage moderate to s vere pain over a period of 24-hours with 
a controlled release formula. The drug is often abused by crushing the pill and snorting or 
injecting the drug to bypass the controlled-release mechanism. In 2010, a new, abuse-deterrent 
formulation of oxycodone was approved by the FDA in 2010. The new formulation makes it 
difficult for users to crush, cut, or dissolve the pill in order to release greater amounts of 
oxycodone. In 2013, the FDA withdrew approval for the original formulation of oxycodone, 
effectively barring the medication. Despite these att mpts to deter abuse, the number of new 
nonmedical oxycodone users has remained relatively stable since 2004, at approximately 
500,000 new users per year (SAMSHA 2013a). However, th e was a slight decrease in new 





remain a substantial public health concern. Oxycodone accounted for 151,000 emergency room 
visits in 2012, almost half of all visits related to narcotic pain relievers (SAMSHA 2103c). It is 
important to note that the vast majority of opioid verdoses occur when the drugs are taken in 
combination with other sedatives and alcohol. These drugs have additive effects in decreasing 
respiration and can be fatal when taken together. As narcotic pain relievers are second only to 
marijuana in illicit use, there has also been substantial recent concern regarding other popular 
drug combinations. However, less is known about the effects of combining pain relievers with 
other types of drugs.  
 
1.3.2 Acute effects of oxycodone 
Oral oxycodone (10mg) decreases respiration and pupil size (Zacny, Paice, and Coalson 
2012). The drug also increases positive subjective effects such as “feel drug effect,” and “like 
drug.” Some negative subjective effects such as “skin-itching” are also increased. Oxycodone 
does not disrupt cognitive performance unless larger doses (20 and 30 mg) of the drug are used 
(Zacny and Gutierrez 2003; Zacny, Paice, and Coalson 2012).  
 
1.4 Poly-drug abuse of amphetamines and opioids 
 Poly-drug abuse is widespread among illicit drug users. For example, in 2009, 67 percent 
of all stimulant-related emergency room visits involved multiple drugs (SAMSHA 2012). Of 
particular concern is the combination of methamphetamine and opiates. Recent data indicate that 
MA-pain reliever combinations accounted for 17.4 percent of all MA-related emergency 





 Despite the significance of poly-drug abuse, the vast majority of human laboratory 
studies on substance abuse are aimed at understanding single drug effects. This is partly due to 
the difficulty and danger in conducting human studies evaluating novel drugs and drug 
combinations. In this regard, preclinical research is a valuable tool for determining the biological 
and behavioral effects of drugs of abuse, especially when the behavioral effects are largely 
uncharacterized. 
It is hypothesized that humans use drug combinations in order to: 1) enhance the effects 
of both drugs, 2) produce a unique profile of effects, 3) allow users to self-medicate, ex. to aid 
sleep, or 4) reduce the unwanted side-effects of one or both drugs. However, to our knowledge 
their have no prior studies investigating the effects of the methamphetamine-oxycodone 
combination. Thus, the third aim was to investigate the rewarding and behavioral effects of the 
methamphetamine-oxycodone combination in a preclinical model, with particular focus on 
whether the combination increases positive and decreases negative effects compared to each drug 
alone. In study 3, we investigated the individual and combined effects of one dose of 
methamphetamine (1 mg/kg, I.P.) and two doses of oxycodone (0.5 and 1 mg/kg, I.P.) on reward 
assessed by conditioned place preference, locomotor ac ivity, sensitization, anxiety assessed by 
the open field test, and short-term memory, assessed by novel object recognition in mice. We 
hypothesized that the drug combination would produce greater reward and reduced anxiety-like 
behavior when compared to either drug alone. The results from this study will provide for the 








1.5 Scientific and Public Health Significance 
Overall, these studies were conducted to further develop the database on the correlates 
and acute effects of marijuana, methamphetamine, and prescription pain relievers. The current 
studies aim to address three gaps in the literature; namely 1) to further elucidate the relationship 
between mental health and marijuana use in college students, 2) to investigate the acute effects of 
marijuana in occasional users that are subjected to rapidly changing shift work, and 3) to begin 
the systematic investigation of the uncharacterized m thamphetamine-oxycodone combination in 
a preclinical model. Further, the present studies utilized a translational, multilevel approach in 













Marijuana is the most commonly used illicit drug in the United States (US) (SAMSHA 
2013a). Data indicate that while cigarette smoking continues to decline, the prevalence of 
marijuana use has been steadily increasing in the past decade among adolescents and young 
adults (Gledhill-Hoyt et al. 2000; Johnston 2013). For example, past 30-day marijuana use 
among young adults aged 18-25 increased from 16.6 percent in 2006 to 18.7 percent in 2012 
(SAMSHA 2013).  
While many young people may not experience any negative effects from marijuana use, 
some studies estimate that 1 in 11 people who ever use marijuana will become dependent 
(Anthony 1994). Persistent, daily smoking of marijuana impairs lung function (Tashkin 2001) 
and withdrawal is associated with a number of deleterious effects such as disrupted sleep, 
decreased appetite, and negative mood states such a irritability, depression, and anger (Budney 
et al. 2007). As legalization and decriminalization of marijuana becomes more widespread, it 
will be important to monitor marijuana use in young adulthood as this is a critical period for the 
development of drug use problems.   
Despite the need for research on marijuana use among young persons, a number of key 
areas are not well understood. First,  marijuana use has commonly been found to be associated 
with the use of other substances among young people (Be l et al. 1997; Gledhill-Hoyt et al. 2000; 
Degenhardt et al. 2001; Wagner and Anthony 2002; Mohler-Kuo et al. 2003). For example, one 
study that sampled undergraduates from 140 universities across the U.S. found that 98.5 to 99% 





2003). In particular, concurrent use of marijuana, cigarettes, and binge drinking is common 
among undergraduates (Schorling et al. 1994; Wechslr et al. 1995; Bell et al. 1997; Gledhill-
Hoyt et al. 2000; Jones et al. 2001; Mohler-Kuo et al. 2003). However, only a handful of studies 
have examined the interaction between marijuana use, binge drinking, and alcohol or drug-
related negative consequences among college students (Shillington and Clapp 2001; Shillington 
and Clapp 2006; Rhodes et al. 2008). Shillington and Clapp 2006 found that undergraduates who 
used both marijuana and alcohol in the past year report d higher rates of substance-related 
negative consequences when compared to students who had nly used alcohol. However, this 
study measured any past year marijuana or alcohol use; therefore it is unknown whether this 
relationship differs depending on frequency of use.  
Secondly, the extent to which marijuana is related to mental health, and particularly 
depression and anxiety among young people remains unclear. Data from studies on the general 
population have shown that depression and substance abuse commonly co-occur (Chen et al. 
2002). In young adults, the cumulative probability of a major depressive episode is 8% for those 
who report using marijuana less than 5 times in their lif , compared to approximately 15% for 
those who used marijuana greater than 6 times in the r life (Chen et al. 2002). Among college 
students, studies examining the relationship between marijuana and mental health have provided 
conflicting information (Buckner et al. 2010; Kouri et al. 1995; Dumas et al. 2002; Cranford et 
al. 2009). One study reported that students who used marijuana daily were indistinguishable 
from occasional users on a range of mental health measures, including prevalence of DSM Axis I 
and II disorders (Kouri et al. 1995). Conversely, another study reported that marijuana use was 





college students (Buckner et al.2010). Thus, the relationship between marijuana use, mental 
health, and academic functioning among undergraduates remains unclear.  
Third, the relationship between stress and marijuana use remains largely uncharacterized. 
Studies have consistently found that college students report stress relief as the most important 
reason for marijuana use (Simons et al. 1998; Simons et al. 2005; CASA 2007). Further, a few 
studies have indicated that coping motives predict cannabis use or cannabis use problems 
(Simons et al. 1998; Simons et al. 2005). However, to our knowledge, the relationship between 
perceived stress and frequency of marijuana use among c llege students has not been 
investigated. 
The current study aims to begin to fill this gap by addressing four aims: 1) To investigate 
the relationship between marijuana use and use of other illicit substances; 2) To examine the 
relationship between marijuana use and alcohol consumption, binge drinking and perceived 
negative consequences from drinking; 3) To investigate the relationship between marijuana use 
and mental health problems; 4) To examine the relationship between perceived stress and 




Data was collected during the Spring 2009 using the Am rican Health Association- National 
College Health Assessment (ACHA-NCHA) (ACHA 2009). The ACHA-NCHA is a national 
survey that consists of approximately 300 variables assessing student health, health-related 
behaviors, access to health information, and health-re ated outcomes. It has been evaluated 





the drug use, mental health, and stress variables from the full instrument. The present study 
included data from 1776 undergraduate students froma highly competitive private institution in 
the northeast US. Participants had the option to skip questions, which produced some variation in 
the sample size according to question. All enrolled un ergraduate students in the primary 
undergraduate academic school were invited to participate in the study (N=5859) and received 
email invitations via their campus email account. Up to three reminders over the course of a 
three week period were sent to non-responders.  A total of 1841 surveys were received (31.4%). 
Participants had the option to be entered into a drawing for gift certificates from a travel provider 
or the bookstore upon completion of the survey. Data from graduate students were excluded 





Participants reported demographic information including age, gender, year in school, 
race/ethnicity, participation in Greek life, and approximate GPA. 
 
2.2.2.2 Marijuana and other substance use 
Participants were asked “Within the last 30 days, on h w many days did you use:” marijuana, as 
well as cigarettes, alcohol, cocaine, methamphetamine, other amphetamines, and hookah. 
Response choices ranged from 1: never used, 2: have used, but not in the past 30 days, 3: 1-2 






2.2.2.3 Binge drinking and negative consequences of drinking 
Participants were asked “Over the last two weeks, how many times have you had 5 or more 
drinks in one sitting?” Response choices ranges from 1:N/A don’t drink, 2:none, 3:1 time, 4:2 
times, 5: 3 times, 6: 4 times, 7: 5 times, 8: 6 times, 9: 7 times, 10: 8 times, 11: 9 times, 12:10 
times. Participants were also asked, “Within the last 12 months, have you experienced any of the 
following as a consequence of your drinking: did something you later regretted, forgot where 
you were or what you did, got in trouble with the police, had unprotected sex, physically injured 
yourself, and physically injured another person.” Response choices ranged from 1 to 3, or 1: N/A 
don’t drink, 2: no, 3: yes. 
 
2.2.2.4 Mental health 
Participants were asked, “Within the past 12 months, have you been diagnosed or treated by a 
professional for depression (or anxiety/substance use disorder)?” Response choices ranged from 
1 to 6, or 1: no, 2:diagnosed but not treated, 3:diagnosed and treated with medication, 
4:diagnosed and treated with psychotherapy, 5:diagnosed and treated with medication and 
psychotherapy, or 6:other treatment. 
 
2.2.2.5 Stress 
Levels of stress during the past 12 months were assssed with a single question, “Within the last 
12 months, how would you rate the overall level of stress you have experienced?” Responses 
ranged from 1 to 5, or 1: no stress, 2: less than average stress, 3: average stress, 4: greater than 






2.2.3 Data Analysis 
First, comparisons on demographic characteristics among students with different levels of 
marijuana use were made using chi-square tests with significance set at p<0.05.  Next, logistic 
regression analyses were used to examine the relationships between marijuana use and other 
drug use, binge drinking, negative consequences of drinking, mental health problems, and 
perceived stress. Results estimating the strength of associations are reported using odds ratios 
with 95% confidence intervals. Odds ratios were adjusted to account for potential confounding 




Marijuana use in the past month was reported by 23.8% (323/1357) of undergraduates in this 
sample. Ten percent (10.2%) reported using marijuana 1-2 days in the past month, 7.1% reported 
using 3-9 days, and 6.6% reported using >10 days. 
 
2.3.1 Demographics  
Current marijuana use was significantly more common among males, white students, seniors, 
and participants of Greek life (Table 1). These demographic factors were also significantly 
associated with frequency of use. Female students were more likely to report no use or light use 
(1-2 days) while males more commonly reported regular se (>10 days; p=.002). Sixty-four 
percent (64%) of the students who reported use of >10 days were white. Black and Asian/Pacific 
Islander students exhibited low frequencies of mariju na use. Sophomore students more 





days or >10 days, p=.029). Seventeen percent (17.8%) of students who used marijuana >10 days 
reported belonging to a fraternity or sorority, compared to 7.8% of those who did not use 
marijuana (p=.0001). There were no significant associations between marijuana use and age or 
approximate GPA. 
 
2.3.2 Marijuana and other substance use 
Current marijuana users, compared to non-users, were significantly more likely to report current 
use of all other substances (Table 2). Frequent marijuana users were also more likely to use all 
other substances when compared to less frequent users and non-users. There was a strong 
association between any marijuana use and alcohol (p=.001). Almost 100% of students who 
reported any marijuana use also reported alcohol use. The strongest association was observed for 
cocaine. Compared to those who reported no past 30-day use, those who used marijuana 1-2 days 
had 6.9 higher odds (95% CI= 4.0 to 11.9) of also repo ting current use of cocaine, those who 
used 3-9 days had 13.7 higher odds (95% CI= 7.8 to 23.9), and those who used >10 days had 
25.8 higher odds (95% CI= 15.0 to 44.2). Further, of the students who reported >10 days of 
marijuana use, a large majority (>80%) also reported current use of cigarettes, hookah, and 
alcohol, almost half (46.7%) reported using cocaine, and 30.3% reported using amphetamines. 
Compared to those who reported no past 30-day use, these students had 14.7 higher odds of 
cigarette use (95% CI= 8.1 to 26.6), 16.8 higher odds of alcohol use (95% CI= 2.3 to 123.0), 
25.8 higher odds of cocaine use (95% CI= 15.0 to 44.2), 7.6 higher odds of amphetamine use 






2.3.3 Binge drinking and negative consequences of drinking 
Frequency of marijuana use was significantly associated with frequency of binge drinking (Table 
3). For example, thirty six percent (36%) of students who used marijuana regularly (>10 days) 
also reported binge drinking on at least three occasions in the past 2 weeks, compared to 23% of 
occasional users (1-2 days) and 6% of students who did not use marijuana. Seventy three percent 
(73.2%) of students who did not use marijuana also did not binge drink. A number of negative 
consequences related to drinking were also significantly associated with marijuana use, even 
when controlling for binge drinking (Table 4). Specifically, students who reported any current 
use of marijuana were also more likely to report regretting something they did while intoxicated, 
forgetting what they did, and having unprotected sex. Frequency of marijuana use was associated 
with drinking-related trouble with the police. Specifically, when compared to non-users, students 
who used marijuana 3-9 days in the past month were 4.0 times more likely (95% CI= 1.3 to 12.4) 
to have an encounter with the police, and those who used >10 days were 7.6 times more likely 
(95% CI= 2.8 to 20.9). Marijuana use was not associated with injuring self or others after 
adjusting for demographic factors.  
 
2.3.4 Mental Health 
Marijuana use was significantly associated with major depressive disorder, anxiety disorders, 
and substance use disorders (Table 5). Specifically, major depression was only significantly 
associated with >10 days marijuana use in the past mon h (AOR: 1.9; 95% CI= 1.0 to 3.6). In 
contrast, anxiety was significantly associated with any marijuana use, with no effect of frequency 







There were no significant associations between the degree of perceived stress and marijuana use 
(Table 6).  
 
2.4 Discussion 
Results of this survey suggest that students who use marijuana are more likely to use alcohol and 
other illicit substances, binge drink and report negative consequences from drinking, when 
compared to students who did not use marijuana. Increased frequency of marijuana use was 
associated with depression, anxiety, and substance-use disorders. Stress was not related to 
marijuana use. Current marijuana use was reported by 23.9% of undergraduates in this sample, 
which is substantially higher than the national aver g  for undergraduates of 15.1% (ACHA 
2009).  
The present results indicate that any marijuana use was associated with increased rates of 
alcohol use, while frequency of marijuana use was associated with increased rates of all other 
drugs use. This data is consistent with previous reports in high school seniors and college 
students (Resnicow et al. 1999). In particular, frequent marijuana users (>10 days) reported using 
many substances at very high rates. Almost all of these students (>80%) also smoked cigarettes 
and hookah and nearly half (46.7%) reported current cocaine use. Thirty percent (30%) also 
reported current amphetamine use.  
 There was a dose-response relationship between marijuana and binge drinking, such that 
regular users engaged in binge drinking more often tha occasional users, who in turn binged 





past month also reported that they did not engage in binge drinking. This data is generally 
consistent with previous reports indicating that college students who reported any current use of 
marijuana were 6.8 times more likely (95% CI 6.11-7.62) to engage in binge drinking (Mohler-
Kuo et al. 2003).   
Any current marijuana use was associated with higher odds of experiencing several 
negative consequences related to drinking; namely students regretting and forgetting what they 
did while intoxicated and having unprotected sex. Frequency of marijuana use was associated 
with drinking-related encounters with the police. Specifically, when compared to non-users, 
students who used marijuana >10 days in the past mon h were 7.6 times more likely to have an 
encounter with the police. In general, this data is consistent with previous reports indicating that 
college students who reported any past-year alcohol and marijuana use were more likely to 
experience negative consequences from substance use than students who only used alcohol 
(Shillington and Clapp 2001; Shillington and Clapp 2006; Rhodes et al. 2008). The present data 
builds on this work by indicating that frequency of use also mediates alcohol-related negative 
consequences, even when controlling for binge drinking. We speculate that poly-drug abuse, and 
in particular concurrent marijuana and alcohol use may be an important risk factor for 
experiencing negative consequences associated with drinking.  
 Frequency of marijuana use was significantly associated with major depression, anxiety, 
and substance use disorders, although to different xtents. Depression was significantly 
associated with regular marijuana use (>10 days), while any marijuana use was associated with 
anxiety. The relationship between marijuana use and depression and anxiety were strongly 





There have been few prior studies examining the relationship between mental health and 
marijuana use among college students, with some conflicting results. For example, Cranford et 
al. 2009 found no association between current marijuana use and symptoms of depression, panic, 
or generalized anxiety disorders in students at a lrge Midwestern university, even when 
examining the role of gender (Cranford et al. 2009). The authors suggested that low base rates of 
marijuana use (12.9%) may have obscured the relationsh p between marijuana and mental health 
problems in more frequent users. On the other hand, Buckner et al. 2010 found that when 
compared to non-users, students who used marijuana at le st once in the past month reported 
more symptoms of a variety of mental health problems, including anxiety, depression, hostility, 
interpersonal sensitivity, paranoia, and psychoticism, although these authors did not investigate 
the effect of gender (Buckner, Ecker et al. 2010). Further, frequent users did not experience more 
mental health problems than infrequent users. The authors concluded that any past 30 day 
marijuana use was associated with a wide range of mental health problems in college students.  
The current results differ from both Cranford et al. 2009 and Buckner et al. 2010. 
Students who smoked marijuana were more likely to repo t diagnosis and/or treatment for 
depression, anxiety, and substance use disorders. Further, the current results indicate a dose-
response for depression. The disparity between the present study and previous studies may be 
due in part to methodological differences. Both Cranford et al. 2009 and Buckner et al. 2010 
used self-report measures of mental health symptomology in the past month. Conversely, the 
present study examined reports of past 12-month diagnosis and/or treatment for mental health 
problems by a professional. Since only a small minority f those with depression, anxiety, and 
substance use disorders seek treatment, the current data suggests that the association between 





mental health problems, and specifically in treatment-seeking subsamples. It is possible that 
these students are more motivated to cope with their m ntal health problems in both adaptive 
(treatment) and non-adaptive ways (drug use).  
Further, the present results are the first data indicating that marijuana use is related to 
diagnosis and/or treatment for anxiety among college students. This is in contrast to previous 
research demonstrating that marijuana use is unrelated to anxiety disorders  or anxiety 
symptomology among undergraduates (Kouri et al. 1995; Dumas et al. 2002; CASA 2007), with 
the exception of some social anxiety symptoms  (Buckner et al. 2006; Buckner et al. 2007; 
Buckner et al. 2008). The present methodology did not ask students to specify the type of anxiety 
disorder. However, the strength of the association suggests that the current results are not simply 
driven by a subset of students with social anxiety disorder. 
It is important to note that many of the mental health measures associated with marijuana 
use were significantly modulated by gender. This data is consistent with a growing literature 
indicating sex differences in the prevalence of depression and anxiety disorders (for review, see 
(Piccinelli and Wilkinson 2000; Bekker and van Mens-Verhulst 2007)). However, many studies 
investigating marijuana use and mental health among c llege students have not investigated the 
role of gender (Kouri et al. 1995; Dumas et al. 2002; CASA 2007).  While not an aim of the 
current study, additional research will be needed in order to tease apart the effects of gender in 
the relationship between marijuana use and mental health. 
There were no significant associations between marijuana use and perceived stress.  This 
result is surprising given the well-established relationship between stress and substance use 
(Hyman and Sinha 2009). However, the low variability n levels of perceived stress may have 





experiencing greater than average or tremendous stre s in the past 12 months. Therefore, it is 
possible that while most students experienced high levels of stress, only a small subset of 
students used substances in order to cope with stress  
 The current results should be interpreted within te context of several limitations. First, 
the sample was comprised of students enrolled in a s gle university located in the Northeast. 
Therefore, the results cannot be generalized to other groups. The current method also utilized a 
convenience sample with a 30% response rate. Further, the current study did not control for non-
response bias. Therefore, students completing the surv y may not be representative of typical 
students at the university. Finally, any conclusion r causal inferences from the current data 
must be tempered due to the cross-sectional nature of th  study. Without longitudinal data, we 
cannot infer the temporal order of substance use and mental health problems. It is possible that 
students who used marijuana become anxious and depressed as a pharmacological or 
psychological consequence of their drug use. It is also possible that anxious and depressed 
students used substances for purposes of self-medication.  
 The current findings suggest that marijuana use among this sample of undergraduates is 
greater than national averages for college students. Frequency of use was associated with 
increased substance use, depression, anxiety, and substance- related problems. Perceived stress 
was generally high among all students, but was not rela ed to marijuana use. Together, this data 
suggests that marijuana use and substance and mental h alth problems are strongly associated in 
undergraduates.  Of particular concern are those studen s who used marijuana >10 days per 
month. These students typically engage in a number of substance use behaviors; almost all 
smoke cigarettes and hookah, almost half report curent cocaine use, and they binge drink at high 





research will be needed to identify specific issues associated with gender, substance use, and 
mental health in college students. Further, outreach efforts need to be made in order to teach 
young adults how to use substances responsibly, recognize substance-related problems, and 







Table 1: Demographics associated with marijuana use among undergraduates 
 
Frequency of 
marijuana use in the 






























































































































































































































Table 2: Marijuana use and any past 30 day other substance use among undergraduates 
Frequency of 
marijuana use in 






1 – 2 days 
(138) 
 
  (n) 
% 
3 – 9 days 
(96) 
 
  (n) 
% 
















                            OR 




3.2 – 6.6 
10.3 
6.2 – 16.9 
15.6 
8.7 – 27.9 
               Adjusted OR 
                        95% CI 
- 4.6 
3.2 - 6.7 
9.8 
5.9 - 16.4 
14.7 
8.1 - 26.6 











                            OR 
                        95% CI 
1.0 
(reference group) 
- - 21.7 
3.0 – 156.5 
               Adjusted OR 
                       95% CI 
- - - 16.8 
2.3 – 123.0 











                           OR 




3.9 – 11.4 
13.9 
8.2 – 23.6 
28.7 
17.2 – 48.0 
               Adjusted OR 
                        95% CI 
- 6.9 
4.0 – 11.9 
13.7 
7.8 – 23.9 
25.8 
15.0 – 44.2 











                            OR 




2.4 – 14.1 
6.4 
2.4 – 16.9 
8.2 
3.3 – 20.7 
               Adjusted OR 
                       95% CI 
- 5.7 
2.3 – 14.0 
5.6 
2.0 – 15.4 
7.6 
2.9 – 20.2 











                            OR 




3.2 – 7.2 
8.7 
5.0 – 15.0 
24.4 
10.6 – 56.2 
               Adjusted OR 
                        95% CI 
- 4.8 
3.2 – 7.1 
8.4 
4.8 – 14.6 
22.3 










Table 3: Marijuana use and binge drinking 
Frequency of marijuana use in 





















     
Number of times had 5 or more 
drinks in one sitting during the 
past 2 weeks 









































     
Frequent binge drinking (3+ 










                                        OR 




2.1 – 5.1 
3.6 
2.2 – 6.0 
6.3 
3.9 – 10.4 
                                 Adjusted OR 
                                  95% CI 
- 3.7 
2.3 – 5.9 
3.3 
1.9 – 5.6 
5.5 
























Table 4: Marijuana use and negative consequences from d inking  

































                                                OR 




1.7 – 3.6 
2.3 
1.5 – 3.5 
2.8 
1.8 – 4.4 
                                   Adjusted OR 
                                            95% CI 
- 2.0 
1.4 – 3.0 
1.5 
1.0 – 2.3 
2.0 
1.2 – 3.2 
     
Forgot what you did  










                                                OR 




1.8 – 3.7 
3.4 
2.2 – 5.3 
2.7 
1.7 – 4.3 
                                   Adjusted OR 
                                           95% CI 
- 1.9 
1.3 – 2.9 
2.0 
1.3 – 3.2 
1.8 
1.1 – 2.9 
     










                                                OR 




1.0 – 9.7 
5.6 
1.9 – 16.6 
10.8 
4.1 – 27.1 
                                   Adjusted OR 
                                           95% CI 
- 2.4 
0.7 – 7.9 
4.0 
1.3 – 12.4 
7.6 
2.8 – 20.9 
     










                                                OR 




2.0 – 5.2 
2.6 
1.5 – 4.7 
3.2 
1.8 – 5.7 
                                   Adjusted OR 
                                            95% CI 
- 2.8 
1.7 – 4.6 
1.8 
1.0 – 3.4 
2.5 
1.3 – 4.6 











                                                OR 




1.2 – 3.2 
2.5 
1.5 – 4.3 
2.0 
1.1 – 3.6 
                                   Adjusted OR 
                                           95% CI 
- 1.4 
0.8 – 2.3 
1.5 
0.9 – 2.7 
1.2 
0.7 – 2.3 











                                                OR 




0.8 – 7.4 
2.6 
0.7 – 9.2 
3.9 
1.3 – 12.1 
                                   Adjusted OR 
                                           95% CI 
- 1.7 
0.5 – 5.5 
 
1.4 
0.4 – 5.3 
2.1 







Table 5: Marijuana use and past 12 month diagnosis and/or treatment for mental health disorders  
Frequency of 
marijuana use in 
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.7 – 2.2 
1.7 
.9 – 3.1 
2.0 
1.1 – 3.6 
             Adjusted OR 
                     95% CI 
- 1.2 
.6 – 2.1 
1.6 
.9 – 3.1 
1.9 
1.0 – 3.6 












                            OR 




1.2 – 3.3 
2.5 
1.4 – 4.3 
2.4 
1.3 – 4.2 
             Adjusted OR 
                     95% CI 
- 1.9 
1.2 – 3.2 
2.3 
1.3 – 4.1 
2.2 
1.2 – 4.1 












                            OR 




.5 – 9.7 
6.4 
2.0 – 20.8 
5.1 
1.3 – 19.0 
             Adjusted OR 
                     95% CI 
- 2.4 
.5 – 12.4 
7.8 
2.1 – 28.7 
5.2 




















Frequency of marijuana 
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.8 – 1.5 
1.0 
.7 – 1.5 
1.3 
.8 – 2.0 
                       Adjusted OR 
                            95% CI 
- 1.0 
.7 – 1.5 
1.0 
.6 – 1.5 
1.3 





Chapter 3: Smoked Marijuana Improves Performance and Mood During Simulated Night 
Shift Work in Marijuana users  
3.1 Introduction 
Drug abuse, if unchecked, could lead to a possible loss to business of more than $200 
billion per year due to increased absenteeism, accidents, and medical costs (Slavit et al. 2009). 
Certain employees are more susceptible to drug use than others. For example, individuals who 
work nonstandard schedules, such as rotating or night shifts, are almost twice as likely to use 
illicit drugs than those working standard day shift schedules (SAMSHA 2008; Frone 2006). This 
issue becomes more concerning when one considers the fact that shift-workers account for 
approximately 20% of all workers in developed countries (Eastman et al. 1995). Rotating shift 
work, particularly night-shift work, requires individuals to alter their normal sleep-wake cycles 
and perform during times when their circadian rhythms make them least alert (for a review, see 
Arendt 2010). Hence, shift-workers have higher rates of workplace-related injuries (Dembe et al. 
2008), performance decrements (Fido and Ghali 2008) and reduced productivity (Akerstedt 
1998).  
Many shift workers use stimulants, sedatives or both in an effort to offset shift work-
related disruptions. Low to moderate doses of stimulants (e.g., amphetamine, caffeine, 
modafinil) have been reported to be effective countermeasures for mood and performance 
decrements caused by sleep deprivation and fatigue (e.g., Hart et al. 2003b, 2006; Walsh et al. 
1990), while sedatives have been demonstrated to improve sleep quality (e.g., Porcu et al. 1997; 
Hart et al. 2003a, 2005). On the other hand, certain types of drug use by shift workers might 





shift work. Cannabis [∆9-tetrahydrocannabinol (∆9-THC)-containing products including 
marijuana and hashish], the most widely used illicit drug in the world (UNODC 2010), is of 
particular concern.  In the United States, 18 state nd Washington D.C. have passed ballot 
initiatives allowing patients to use marijuana on the advice of their physicians. In addition, 
marijuana is the most commonly detected illicit drug in the workplace, accounting for 
approximately 50% of all positive urine toxicology screens (Quest Diagnostics 2010). Of course, 
because it may take 1 to 10 weeks for marijuana to be fully cleared from the system (Ellis et al. 
1985; Huestis et al. 1996), a urine toxicology screen that is positive for marijuana metabolites 
does not provide information about time of use, nor an individual’s possible level of intoxication 
or her/his ability to perform workplace-related operations. The sheer number of marijuana users 
combined with data showing that 2 million Americans (i.e., 1.6% of the workforce) report being 
intoxicated on the drug while at work at some point (Frone 2006), however, suggest the 
importance of understanding the potential contributions of marijuana use to workplace 
productivity and safety.  
Data from laboratory studies assessing the acute effects of smoked marijuana in 
experienced users show that the drug produces paradoxic l effects; it enhances ratings of 
alertness and stimulation (e.g., Haney et al. 1999; Hart et al. 2001, 2002) but facilitates sleep 
(e.g., Vandrey et al. 2011). The drug’s effect on performance depends upon the marijuana use 
history of research participants. That is, infrequent users tend to display marked disruptions 
during intoxication (e.g., Fant et al. 1998; Curran et al. 2002; D’Souza et al. 2004), whereas 
frequent users show little performance alterations (e.g., Hart et al. 2001, 2010; Vadhan et al. 
2007; Ramaekers et al. 2009; Schwope et al. 2012). One consistent disruptive effect observed in 





complete cognitive tasks (e.g. Hart 2001). This finding could have important implications in real 
world settings, such as in the workplace, where rapid decisions may be required.    
There is little information about the effects of marijuana on performance or other 
measures (e.g., mood, sleep) of individuals subjected to work conditions that mimic those in the 
natural ecology. Thus, the purpose of this study was to examine the effects of smoked marijuana 
on the daytime and nighttime performance during shift work in current marijuana smokers. We 
developed a controlled laboratory model of shift work in order to more closely model the real 
world work environment. Participants live in a residential laboratory and work 3 days on a day 
shift (0830-1730h) and 3 days on a night shift (0030- 930h), with shift condition switching 
several times during the study. This within-participants model facilitates the examination of 
abrupt work shift change-related alterations in human behavior and the interactive effects of 
drugs on these alterations. We hypothesized that marijuana would exacerbate night-shift-related 




Ten healthy research participants (mean age [±SD] 27.2 ± 5.6) completed this 23-day 
residential study: three were female (two Black, one Hispanic) and seven were male (three 
Black, one Hispanic, one Native American, and two White). They were solicited via word-of-
mouth referral and newspaper advertisement in New York City. Participants’ formal education 
ranged from 10 to 16 years (mean 13.2) and all report d previous experience working irregular 





1.2 ± 0.4 marijuana cigarettes/smoking occasion. Nie reported occasional use of alcohol (1–6 
drinks/week), and eight smoked tobacco cigarettes (1–20 cigarettes/day). Participants reported 
that they used other drugs infrequently: three had used methylenedioxymethamphetamine 
(MDMA) less than a total of five times, three used illicit prescription opioids less than a total of 
three times, two used psychedelic mushrooms twice, on  used cocaine once, and one reported 
using d-lysergic acid diethylamide (LSD) once. Urine toxicology analyses during the screening 
process confirmed the absence of illicit drug use oth r than marijuana (all participants tested 
positive for ∆9-THC only). All volunteers passed comprehensive medical and psychological 
evaluations and were within normal weight ranges according to the 1983 Metropolitan Life 
Insurance Company height/weight table (mean body mass index: 25.3 ± 4.0).  
Volunteers were informed that the purpose of the study was to evaluate the effects of 
marijuana on cognitive performance and mood of shift workers. Each participant signed a 
consent form approved by the New York State Psychiatric Institute’s Institutional Review Board 
and was fully informed about experimental and drug conditions at the end of the study. 
Participants were compensated at a rate of $70 per day. 
 
3.2.2 Laboratory 
Three groups of 3-4 individuals stayed in a residential laboratory in the New York State 
Psychiatric Institute (Foltin et al. 1996; Hart et al. 2003a). Each participant resided in a private 
bedroom, equipped with a bed, desk, Macintosh computer system, refrigerator, microwave, 
toaster, food preparation area, and a barcode scanner (Worthington Data Solutions, Santa Cruz, 





participants were free to engage in social and recreational activities, such as watching videotaped 
films, playing video games and board games, reading, a d exercising. Food and tobacco 
cigarettes were available ad libitum during waking hours. To enable continuous observation of 
behavior, cameras and microphones are located in the common social area and in bedrooms, but 
not in bathrooms, showers, or private dressing areas. Communication between participants and 
research staff was kept to a minimum and primarily ccomplished via computers in each 
participant’s bedroom.  
 
3.2.3 Pre-Study Training 
Prior to beginning the study, participants completed 2 sessions of training (3-4 hours per 
session), during which they were familiarized with laboratory and study procedures and trained 
on the computerized tasks that would be used in the study. By the end of the second session, 
none of the participants' performance on any of the tasks varied by more than 10 percent. The 
purpose of training is so that the tasks are well-learned prior to study participation to minimize 
the effect of learning on any task performance during the study. On a separate day, they smoked 
3 puffs from a single marijuana cigarette (3.56% ∆9-tetrahydrocannabinol [THC]) to provide 
them with experience with the study drug and to monitor any potential unusual reactions.  No 
unusual responses were observed. 
 
3.2.4 Design 





experienced six dose/shift combinations: three puffs o  placebo + day and night shift, 1.9% ∆9-
THC concentration + day and night shift, and 3.56% ∆9-THC concentration + day and night 
shift. During the night shift, participants were awakened at 0015, performed computerized tasks 
(described below) from 0030 to 0930, and went to bed at 1600; during the day shift, they were 
awakened at 0815, performed computerized tasks from 0830 to 1730, and went to bed at 2400.  
Shifts alternated 3 times during the study, and shift conditions were separated by an "off" day, 
during which participants were not on a work schedul  b t were required to go to bed 8.25 hrs 
prior to the next shift as they had done during other days. Two groups of participants (N = 7) 
began on the night shift and one group (N = 3) began on the day shift. Placebo or marijuana 
(1.9% or 3.56% ∆9-THC) was smoked once per day, one hour after waking (0915 on the day 
shift and 0115 on the night shift).  Days 8 and 16 were "drug washout" days during which 
participants smoked placebo marijuana before being switched to another drug condition.  In 
order to minimize potential confounding effects, presentation of ∆9-THC concentrations were 
systematically varied between groups of 3-4 participants, although dose order was the same for 
all subjects in a cohort.   
 
3.2.5 Procedure 
Participants moved into the residential laboratory he day before the study began to 
habituate to inpatient living conditions.  On each study day, participants first completed baseline 
cognitive/psychomotor tasks, a 44-item subjective-eff cts visual analog questionnaire, and a 
visual analog sleep questionnaire (described below).  Then, they were weighed (but were not 





computerized task batteries, composed of the subjective-effects questionnaire and 
cognitive/psychomotor tasks, were completed.  Participants were given a 15-min break between 
each task battery.  From 1000 (0200) to 1245 (0445), participants completed 4 task batteries and, 
after a 1.5-hr lunch break period, they completed 4 a ditional task batteries from 1415 (0615) to 
1700 (0900).  Beginning at 1700 (0900), participants had access to activities available in the 
social area.  Two films were shown daily, beginning at 1800 (1000) and 2100 (1300).  Lights 
were turned out at 2400 (1600) for an 8.25-hr sleep period.  
 
3.2.6 Subjective-effects and Cognitive/Psychomotor Battery 
The 30 min computerized task batteries consisted of a visual analog questionnaire and 
cognitive/psychomotor tasks. The visual analog questionnaire is a 3 min task comprised of a 
series of 100-mm lines labeled "not at all" at one e d and "extremely" at the other end (Hart et 
al., 2006).  The lines were labeled with adjectives d cribing a mood (e.g., “I feel…” “alert,” 
“depressed,” “social”), a drug effect (e.g., “I feel…” “stimulated,” “a good drug effect,” “a bad 
drug effect”), or a physical symptom (“I feel nauseous,” “I have a headache,” “My heart is 
beating faster than usual”). In addition, 15 min after smoking the marijuana cigarette, 
participants completed a 2 min drug-effect questionnaire (DEQ) during which they rated “good 
effects” and “bad effects” on a five-point scale: 0=“not at all” and 4=“very much.” They also 
rated how “strong” the drug effect was as well as their desire “to take the drug again.” Lastly, 
participants rated how much they liked the drug effect on a nine-point scale: -4 =“disliked very 





The computerized psychomotor task battery was selected because it had been used in 
multiple other studies assessing the effects of drugs on performance. This facilitates the 
comparison of data collected in the current study with previous findings. The battery consisted of 
five tasks: 1) the Digit Recall Task; 2) the digit-symbol substitution task (DSST); 3) the divided 
attention task (DAT); 4) the rapid information task (RIT); and 5) the Repeated Acquisition Task 
(RA task). 
During the 2 min Digit Recall task, an 8-digit number was displayed for 3 sec on the 
computer screen. Participants were instructed to enter the number correctly while it was on the 
screen and again after it had disappeared from the screen. They were also told that they would be 
asked to reproduce and recognize the number near th end of the battery. This task was designed 
to assess changes in immediate and delayed recall (see Hart et al., 2001). 
The DSST is a 3-min task (McLeod et al., 1982) thatconsisted of nine random three-row 
´ three-column squares (one square blackened/row) displayed across the top of the computer 
screen. Each array was associated with a number (1-9). A randomly generated number appeared 
at the bottom of the screen, indicating which of the arrays should be reproduced on the nine-key 
keypad attached to the computer. Participants were instructed to reproduce as many patterns as 
possible by entering the patterns associated with the randomly generated numbers. This task was 
designed to assess changes in visuospatial processing. 
The DAT is a 5-min task that combines concurrent pursuit-tracking and vigilance tasks 
(Miller et al., 1988). Participants tracked a moving circle on the video screen using the mouse, 





screen. Accurate tracking of the moving stimulus increased its speed proportionately. This task 
was designed to assess changes in vigilance and inhibitory control. 
During the 7 min RIT, a series of digits was presented at the rate of 100 digits per min, 
and subjects were instructed to press a response button as quickly as possible whenever they 
detected sequences of three consecutive odd or three consecutive even digits (Wesnes and 
Warburton, 1983). A point was earned for each corret “hit” and a point was deducted for each 
“miss” or “false alarm.” Participants were instructed to earn as many points as possible during 
the task. This task was designed to assess changes in su tained concentration and inhibitory 
control. 
At the start of the 3-min RA task, participants were instructed to learn a 10-
response sequence of button presses. A position counter incremented by one each time a 
correct button was pressed, and remained unchanged after an incorrect response. The 
points counter increased by one each time the 10-response sequence was correctly 
completed. The sequence remained the same throughout the task, but a new random 
sequence was generated for each subsequent task battery. Participants were instructed to 
earn as many points during the task as possible by pressing the buttons in the correct 
sequence. This task was designed to assess changes in learning and memory (see Kelly et 
al., 1993).  
 
3.2.7 Sleep Monitoring 
Objective sleep was measured using the portable Nightcap® sleep systems, which 
consisted of a headband worn by participants while t ey slept (Ajilore et al., 1995; Cantero et al., 





sleep, and a body movement sensor in the headband detected and recorded movements.  The 
system provided measures of total sleep time, sleep onset latency, rapid eye movement latency, 
non-rapid eye movement sleep time, and sleep efficincy (total sleep time as a percentage of time 
in bed) and has been reported to correspond well to traditional polysomnography and subjective 
reports of sleep quality (Ajilore et al., 1995).  In addition to wearing the portable sleep monitor, 
participants completed a visual analog sleep questionnaire each morning.  This questionnaire 
consisted of a series of 100 mm lines labeled "not at all" at one end and "extremely" at the other 
end.  The lines were labeled: "I slept well last night," "I woke up early this morning," "I fell 
asleep easily last night," "I feel clear-headed this morning," "I woke up often last night," "I am 
satisfied with my sleep last night," and a fill-in question in which participants were asked to 
estimate the number of hours they thought they slept the previous night (Haney et al., 2001). 
 
3.2.8 Drug 
One hour after waking each morning, participants were given one 1-gm marijuana 
cigarette (0, 1.9, or 3.56% ∆9-THC: provided by the National Institute on Drug Abuse).  These 
concentrations of ∆9-THC were selected because performance impairments at similar doses have 
been well-established in this laboratory and others (Azorlosa et al. 1992; Chait and Perry 1994; 
Ward et al. 1997; Hart et al. 2001, 2002). Cigarettes were smoked using a cued-smoking 
procedure, which produces ∆9-THC concentration-dependent changes in heart rate and 
subjective-effect ratings (see Foltin et al. 1987; Hart et al. 2001). Colored lights (mounted on the 
ceiling of the social/recreational area) signaled ‘ight the cigarette’ (30 s), ‘get ready’ (5 s), 





manner, with a 40-s interval between each puff. Cigarettes were tightly rolled at both ends and 
were smoked through a hollow plastic cigarette holder so that the contents were not visible. 
Twenty-four hours prior to administration, cigarettes were removed from a freezer, where they 
were stored in an airtight container, and humidifie at room temperature.  
 
3.2.9 Data Analysis 
Data from off and drug washout days (days 4, 8, 12, 16, 20) were not included in the 
analyses. The area under the curve (AUC) for the subjective effects visual analog questionnaire 
and the cognitive/psychomotor tasks was determined using the trapezoidal method (Tallarida and 
Murray 1981). Peak subjective-effect and cognitive psychomotor data were analyzed similarly. 
For the sake of brevity, data for the AUC analyses ar  discussed primarily because significant 
drug effects were similar for peak and AUC analyses.  
Data were analyzed using 3-factor repeated-measures analyses of variance (ANOVA): 
the first factor was ∆9-THC concentration (placebo, 1.9, 3.56%), the second factor was shift 
condition (day, night), and the third factor was day within condition (1, 2, 3). For all analyses, 
ANOVAs provided the error terms needed to calculate planned comparisons that were designed 
to answer two questions: (1) are cognitive/psychomot r task performance and subjective-effects 
ratings disrupted during the night shift, and (2) does marijuana alter night shift-related 
disruptions? To evaluate night shift-related disruptions, each day of placebo was compared to the 
corresponding night of placebo (e.g., the first dayof placebo during the day shift vs. the first 
night of placebo during the night shift). To evaluate the effects of marijuana on night shift-





another drug condition (e.g., the first night of 1.9% ∆9-THC during the night shift vs. the first 
night of placebo during the night shift). Marijuana-related effects during day-shift work were 
evaluated similarly. Huynh-Feldt corrections were us d when appropriate and p-values < 0.05 
were considered statistically significant. 
 
3.3 Results 
3.3.1 Effects of Shift Condition 
3.3.1.1 Cognitive Performance 
The upper panels of Figure 1 illustrate how selected performance varied between th  day 
and night shift when participants received placebo. Planned comparisons revealed that the 
number of digits entered in the Digit Recall Task and the number of hits on the RIT were 
significantly reduced during all three nights that p rticipants worked on the night shift compared 
to the corresponding days on the day shift (p < 0.006). In addition, the number of completed 
trials on the repeated acquisition task was decreased on the first and third nights of the night shift 
(p < 0.03). As shown in Tables 3-4, other performance measures (e.g., DAT: speed and hit 






Figure 1. Upper panel: AUC values for total trials (RA), total number of hits (RIT), and total 
number of digits entered as a function of shift condition and day within condition. §Significant 
difference between the day and night shift conditions for that day following placebo 
administration (p<0.05).  Bottom panel: AUC values for total trials (RA), total number of hits 
(RIT), and total number of digits entered as a functio  of ∆9-THC concentration and day of the 
night-shift condition. *Significant difference between placebo and ∆9-THC concentration for that 
day (p<0.05). #Significant difference between 1.9 and 3.56% ∆9-THC for that day (p<0.05). 








3.3.1.2 Subjective-effects ratings 
The upper panels of Figure 2 show how selected subjective-effect ratings varied between 
the day and night shifts when participants received placebo. Ratings of “Self-Confident” were 
significantly decreased during all three nights of the night shift compared to the corresponding 
day shift days (p < 0.05). Conversely, ratings of “Tired” and “Miserable” were significantly 
increased during two of the three nights of the night shift (p < 0.04). Tables 2-4 show that several 
other subjective-effect ratings (e.g., “Unmotivated” and “Talkative”) were altered significantly 
as a function of shift condition. 
3.3.1.3 Sleep 
The upper panels of Figure 3 display how objective and subjective measures of sleep 
varied between the day and night shifts when participants received placebo. Total sleep time, as 
measured by the Nightcap®, was decreased across all three days that participants worked on the 
night shift, but this effect was statistically significant only on the first and third day of the night 
shift (p < 0.004). Similarly, subjective estimates of total sleep time and ratings of sleep 
satisfaction were significantly decreased on the first day of the night shift (p < 0.006). 
3.3.1.4 Cigarette Smoking 
There was no significant effect of shift on the number of cigarettes smoked by 









Figure 2. Upper panel: AUC values for visual analog scale ratings of 'Self-Confident,' 'Tired,' 
and 'Miserable' as a function of shift condition and day within condition. §Significant difference 
between the day and night shift conditions for thatday following placebo administration 
(p<0.05).  Bottom panel: AUC values for visual analog scale ratings of 'Self-Confident,' 'Tired,' 
and 'Miserable' as a function of ∆9-THC concentration and day of the night-shift condition. 
*Significant difference between placebo and ∆9-THC concentration for that day (p<0.05). Error 








3.3.2 Effects of Marijuana 
3.3.2.1 Cognitive Performance 
The bottom panels of Figure 1 show how marijuana affected performance during the 
night-shift condition. (The night-shift data in the upper panels are the same data shown under the 
placebo condition in the bottom panels.) The 3.56% ∆9-THC concentration improved 
performance on the repeated acquisition task (increased the number trials) and RIT (increased 
the number of hits) on at least two of the three nights relative to placebo (p < 0.03). Both active 
concentrations increased the number of digits enterd during the Digit Recall Task on at least 
two of the three nights of the night shift (p < 0.003). The lower concentration also significantly 
increased the number of hits on the RIT on the third n ght (p < 0.02). Other significant 
performance effects produced by marijuana during the night shift are shown in Tables 2-4.  
In contrast to the beneficial effects marijuana produced during night shift work, it had 
limited effects on performance during the day shift. The 1.9% ∆9-THC concentration 
significantly decreased the number of hits on the RIT on all three days of day shift work (p < 
0.04), increased the number of misses on the RIT on the first two days (p < 0.05), and decreased 
the maximum speed on the DAT on the first and third day (p < 0.05).  
 
3.3.2.2 Subjective-effects ratings 
The bottom panels of Figure 2 display how marijuana ffected subjective-effect ratings 
during the night-shift condition. Both active concetrations significantly increased ratings of 
“Self-Confident” on all three nights (p < 0.03). The 3.56% ∆9-THC concentration decreased 
subjective ratings of “Tired” on the first night (p < 0.05) and both concentrations significantly 





increased ratings of “Stimulated” on all three nights (p < 0.05), while both concentrations 
decreased ratings of “Miserable” on at least two of the three nights (p < 0.04). As shown in Table 
2-4, other subjective-effects ratings were also altered significantly during night shift work. 
Notably, both concentrations significantly increased ratings of “Good drug effect” and “High” on 
all three nights (p < 0.0001) and increased ratings of “Forgetful” on at le st two nights of the 
night shift (p < 0.05).   
During the day shift condition, both active concentrations of ∆9-THC significantly 
increased ratings of “Good drug effect,” and “High” on all three days (p < 0.001). Both 
concentrations also significantly increased ratings of “Stimulated” on all three days of the day 
shift (p < 0.03). 
 
3.3.2.3 Sleep 
The bottom panels of Figure 3 display the effects of marijuana on sleep measures during 
the night shift condition. The 3.56% ∆9-THC concentration significantly increased total sleep 
time on the first day, as measured by the Nightcap® (p < 0.03); this concentration also increased 
estimations of total sleep time and subjective ratings of sleep satisfaction on the first day (p < 
0.05). During the day shift condition, there were no significant effects of ∆9-THC on objective or 
subjective measures of total sleep time or sleep satisfaction.  
 
3.3.2.4 Cigarette Smoking 
There was a significant effect of ∆9-THC concentration on the number of cigarettes 





an average of 1 less cigarette when they received 3.56% ∆9-THC (placebo= 6.85±0.64; 1.9% ∆9-
THC =6.56±0.69; 3.56% ∆9-THC= 5.23±0.61). 
 
 
Figure 3. Upper panel: Total sleep time from the previous evening as measured by the Nightcap® and 
selected mean subjective effects from the sleep questionnaire as a function of shift condition and day
within condition. §Significant difference between the day- and night-shift conditions for that day 
following placebo administration (p<0.05). Bottom panel: Total sleep time from the previous evening as 
measured by the Nightcap® and selected mean subjective effects from the sleep questionnaire as a 
function of ∆9-THC concentration and day of the night-shift condition. *Significant difference between 
placebo and ∆9-THC concentration for that day (p<0.05). #Significant difference between 1.9 and 3.56% 
∆







Psychomotor performance and subjective-effect ratings were altered during the night shift 
compared to the day shift: performance and a few subjective ratings were decreased (e.g., “Self-
Confident”), whereas other ratings were increased (e.g., “Tired”). These results are consistent 
with data from previous investigations on the effects of rotating work schedules on human 
performance and mood under controlled laboratory conditions (e.g., Reid and Dawson 
2001; Sharkey et al. 2001; Hart et al. 2003a, b). Contrary to our prediction, smoked marijuana 
did not exacerbate night shift-related disruptions. I tead, the drug mainly attenuated night shift-
related disruptions in regular marijuana smokers.   
As expected, when participants worked on the night shif and received placebo, their 
performance was disrupted in several domains. The most pronounced alterations were noted on 
tasks that measured attention and vigilance. Specifically, participants performed significantly 
worse on the DAT (measures of speed and hit latency) and the RIT (measures of hits and misses) 
on all 3 nights of the night shift. In addition, inh bitory control disruptions, as measured by two 
separate tasks (i.e., DAT: false alarms and RIT: false larms), were observed on 2 of the 3 
nights. These findings replicate data collected under similar conditions (Reid and Dawson 
2001; Sharkey et al. 2001; Hart et al. 2003a, b, 2005, 2006) and confirm that individuals who are 
required to make abrupt work shift schedule changes ar  prone to performance decrements. The 
study design used here is similar to irregular or rapidly rotating shift schedules in the natural 
ecology (Sallinen and Keckland 2010), and the current data are also congruent with recent 
findings from a study conducted in a more naturalistic setting. Chang et al. (2011) compared the 
performance of nurses working 2, 3, or 4 consecutive n ghts and found more perceptual and 





who worked four consecutive nights. The results indicate that performance disruptions are more 
pronounced during the first few days of the night shift. Taken together, the data suggest that an 
acclimation period greater than 24 hours might be necessary in order to offset shift schedule 
change-related disruptions.   
One possible explanation for the performance decrements observed during the night shift 
is that the abrupt change in work schedule produced sleep disruptions that affected next-day 
performance. Indeed, objective and subjective sleep m asures partially support for this view. 
Data from the Nightcap® showed that total sleep time was reduced by 2.5 hrs on the first night 
of the night shift. These data replicate previous findings indicating that night shift work is 
associated with 2-4 hrs of reduced sleep (Torsvall et a . 1989; Åkerstedt 1995; Niu et al. 2011). 
Furthermore, participants reported reduced sleep quality on the first night of the night shift: e.g., 
their estimates of total sleep time and ratings of leep satisfaction were significantly lower. Mood 
was also disrupted during the night shift. Participants reported feeling less “Self-Confident” on 
all three nights they worked on the night shift and e orsed items indicating that they were tired, 
miserable, and unmotivated on at least two nights. These data are consistent with previous 
findings when participants were abruptly placed on a night shift work schedule (Hart et al. 
2003a, b). 
It is noteworthy that performance disruptions persisted throughout the three nights that 
participants worked on the night shift, while measure  of daytime sleep improved by the second 
day. One potential reason for these data is short-term circadian misalignment. Working on the 
night shift forces the body to function during the circadian trough of alertness, potentially 
compounding problems caused by sleep deprivation. Thus, the enduring performance disruptions 





prevents optimal performance. Indeed, previous research has indicated that the speed of circadian 
adjustment is approximately 1 hr per day, meaning that i  would require at least 1 week for a 
diurnal cycle to switch to a nocturnal circadian cycle (Wever 1980; Hastings 1998). While we 
did not assess circadian phase, the current data show that daytime sleep improved over the course 
of three nights of night-shift work. Therefore, we speculate that a longer acclimation period to 
night shift conditions would also improve performance.  
We predicted that smoking marijuana would exacerbat performance disruptions during 
the night shift. This hypothesis was not supported. The drug produced limited effects on 
performance on the first night of the night shift and attenuated decrements on subsequent nights. 
On the second night, marijuana attenuated performance disruptions on four measures. Both 
active ∆9-THC concentrations reduced disruptions in inhibitory control (e.g., RIT: false alarms) 
and recall (e.g., Digit task: total entered) and only the larger concentration lessened disruptions 
in sustained attention (e.g., RIT: hits and misses). On the third night, marijuana also attenuated 
shift-related performance decrements: both ∆9-THC concentrations lessened disruptions in 
domains measuring reaction time (e.g., DAT: hit latency), vigilance/sustained attention (e.g., 
DAT: misses and maximum speed; RIT: hits), and recall (e.g., Digit: total entered).  
To our knowledge the current study is the first investigation of marijuana-related effects 
during simulated shift work, making it difficult to compare our results to earlier research in this 
area. Previously, we reported that stimulant medications such as methamphetamine and 
modafinil attenuated many night shift related performance decrements (Hart et al. 2003b, 2006). 
It is possible that the stimulant-like properties of marijuana played a role in decreasing night 
shift-related performance decrements observed in the current study. When participants smoked 





stimulated and less tired on the majority of nights. Thus, we speculate that the stimulant-like 
effects of marijuana may have counteracted night shift related decrements.  Another possible 
explanation for the current results is that smoking marijuana prior to the work period aided in 
overall sleep recovery during the night shift. The larger concentration increased both objective 
and subjective measures of total sleep time, and improved sleep quality as measured by ratings of 
“Satisfied Sleep.” In general, marijuana-related effects on sleep are congruent with previous data 
investigating the effects of the sleep medication zlpidem on next-day performance of 
individuals subjected to abrupt shift schedule changes (Hart et al. 2003a, 2005). Together, these 
observations suggest that marijuana cigarettes containi g low to moderate ∆9-THC 
concentrations offset some disruptions caused by work shift schedule changes.  
This interpretation should be considered in the context of several important caveats. The 
current study did not assess a broad range of ∆9-THC concentrations. It is likely that increasing 
∆
9-THC concentrations or the number of joints smoked would have exacerbated night shift-
related disruptions. Similarly, the current study participants were experienced marijuana users 
who smoked multiple times each week (i.e, about three times per week). It is well documented 
that frequent marijuana users show fewer behavioral signs of disruption during intoxication than 
infrequent users. Thus, the generality of the present findings might be limited, as a different 
pattern of results might have been obtained if infrequent users were studied. Relatedly, it is 
possible that because study participants were regular marijuana smokers, they may have 
experienced marijuana withdrawal symptoms during placebo conditions and such symptoms 
could have influenced study findings. This seems les ikely because withdrawal symptoms are 





cigarettes on a daily (or near daily) basis (Haney 2005). Heavy marijuana smokers were 
excluded from this study in order to avoid this potential confound.   
In conclusion, these data demonstrate that performance, sleep, and mood are disrupted 
during night shift work when participants are subjected to abrupt shift changes. The data further 
show that marijuana cigarettes containing low to moderate ∆9-THC concentrations can decrease 
some night shift-related performance and mood disruptions. Because these are the first data 





Table 1. Study Design 
Study day Shift condition Drug Condition (∆9-THC%) 
1-3 Day 0 
*4 Off Off 
5-7 Night 1.9 
*8 Night 0 
9-11 Night 3.56 
*12 Off Off 
13-15 Day 3.56 
*16 Day 0 
17-19 Day 1.9 
*20 Off Off 
21-23 Night 0 
 
Note. *Indicates days that were not included in data analyses; Off = off days 
Shift condition order was varied across participants 
∆
9-THC order was counterbalanced across participants  























Table 2.  Effects of Shift Condition and Smoked Marijuana on Subjective Effects on Day 1 
Conditions 
  Pbo Day  Pbo Night  1.9% Δ
9
-THC Day 1.9% Δ
9
-THC Night  3.56% Δ
9
-THC Day 3.56% Δ
9
-THC Night 













Subjective Effects                


























































































Data are represented as AUC values  
df= 1,40 
Pbo = placebo 
§
 p < 0.05, significant difference between the placebo day and placebo night conditions 
* p < 0.05, significant difference from the placebo condition 
 †








Table 3.  Effects of shift condition and smoked marijuana on psychomotor performance and subjective effects on Day 2 
 
Conditions 
  Pbo Day  Pbo Night  1.9% Δ
9
-THC Day 1.9% Δ
9
-THC Night  3.56% Δ
9
-THC Day 3.56% Δ
9
-THC Night 













Performance Effects                






























                
                
Subjective Effects                











































































Data are represented as AUC values  
df= 1,40 
Pbo = placebo 
§
 p < 0.05, significant difference between the placebo day and placebo night conditions 
* p < 0.05, significant difference from the placebo condition 
 †








Table 4. Effects of shift condition and smoked marijuana on psychomotor performance and subjective effects on Day 3 
Conditions 
  Pbo Day  Pbo Night  1.9% Δ
9
-THC Day 1.9% Δ
9
-THC Night  3.56% Δ
9
-THC Day 3.56% Δ
9
-THC Night 















Performance Effects                


































2.09  4.30 
(0.30) 
0.75 3.80  
(0.20) 















20.25*  0.70 
(0.30) 
0.25 1.20  
(0.47) 
9.00* 













































































                
Subjective Effects                































































Data are represented as AUC values  
df= 1,40 
Pbo = placebo 
§
 p < 0.05, significant difference between the placebo day and placebo night conditions 
* p < 0.05, significant difference from the placebo condition 
 †





Chapter 4: Poly-drug abuse: rewarding and behavioral effects of methamphetamine, 
oxycodone, and their combination 
 
4.1 Introduction 
Abuse of drug combinations has increased dramatically in recent years. Between 2009 
and 2011, emergency department visits associated with the misuse of multiple drugs increased 
116 percent. Abuse of drug combinations represents the majority of all drug-related visits to the 
emergency room (SAMSHA 2013). Further, two thirds (66.4%) of patients seeking substance 
abuse treatment report polydrug abuse (SAMSHA 2013). Despite the popularity of drug 
combinations, there is a paucity of research examining the unique issues associated with taking 
multiple drugs simultaneously. A lack of understanding about the consequences of drug 
combinations may obscure our view of substance abuse and hamper treatment efforts.  
 One popular speculation put forth to account for polydrug abuse is that drug interactions 
enhance the positive and decrease the negative effects of the combined drugs (Hunt et al. 2009). 
Data examining the cocaine-heroin “speedball” combination, the most frequently studied 
combination in animals, generally support this view. Several studies have found that 
combinations of low doses of cocaine and heroin are more reinforcing than either of the drugs 
alone (Rowlett and Woolverton 1997; Ranaldi and Munn 1998; David et al. 2001; Rowlett et al. 
2005; Martin et al. 2006; Rowlett et al. 2007). Fewer studies have examined the effects of this 
drug combination on locomotor activity or other behavioral and cognitive measures in rodents 
(David et al. 2001; Leri et al. 2003; Leri et al. 2003; Cruz et al. 2011). This is a glaring gap in 
our knowledge because these measures may be of particular importance for understanding the 





 To our knowledge, there have been no prior animal or human studies documenting the 
consequences of the methamphetamine/oxycodone combination. This is somewhat surprising 
because methamphetamine is the most widely abused amphetamine (SAMSHA 2011) and its 
abuse has generated a considerable amount of concern. In addition, over the past decade the 
misuse of prescription pain relievers, especially ox c done, has dramatically increased (Crane 
2003). In fact, 17% of all methamphetamine-related emergency room visits also involve 
oxycodone (SAMSHA 2010). 
 Preclinical research is an important tool for determining the biological and behavioral 
effects of drugs of abuse. This is especially true in the case of novel drugs and drug combinations 
where behavioral effects are largely uncharacterized, making the danger and difficulty of human 
research unwarranted. However, limited communication between preclinical and clinical 
researchers often results in the use of experimental me sures that do not overlap and drug doses 
that do not translate well. A goal of the present experiment was to examine the effects of low 
doses of the MA/ oxy combination in measures that could be easily compared to data from a 
human study on the same topic. To this end, the current experiment included a range of measures 
aimed to characterize the subjective and cognitive effects of low doses in a preclinical model. 
The primary goal of the present experiment was to systematically investigate the 
behavioral and locomotor effects of the methamphetamine-oxycodone combination. A second 
goal was to evaluate whether this combination enhances positive and decreases negative effects 
compared to each drug alone. To address these questions, we first used a conditioned place 
preference paradigm to compare the effects of methamp etamine, oxycodone, and their 





short-term memory was assessed during acute intoxication and one week after the last drug 
administration.  
4.2 Methods 
4.2.1 Animals and housing 
Subjects were adult male C57BL/6N mice 7-9 weeks of age (Jackson Laboratory, Bar Harbor, 
ME). Mice were housed individually in transparent polycarbonate cages (27 × 16.5× 12 cm) and 
placed in sound attenuating, ventilated chambers (Phenome Technologies Inc. Lincolnshire, IL).  
The room was maintained at 23 ± 2 0C and 72% humidity. Standard mouse chow (Purina, St. 
Louis, MO) and water were available ad libitum. Animals were adapted to a 12:12 light:dark 
cycle (200 lux), with lights off at zeitgeber time 1200 (ZT 12) and on at ZT 0000 (ZT 0) for 14-
16 days before the start of the experiment.  All behavioral experiments were conducted between 
ZT 2 and 8 during lights on. Animals were cared for in accordance with the Columbia University 
Institutional Animal Care and Use Committee and Animal Welfare regulations.  
 
4.2.2 Preparation of drugs 
Stock solutions of methamphetamine (MA) hydrochloride and oxycodone (oxy) hydrochloride 
(Sigma-Aldrich Inc., St. Louis, MO) were prepared (saline vehicle) so as to keep injection 
volumes consistent among groups as follows: oxy1 = 0.0625 mg/ml, oxy2 = 0.125 mg/ml , MA-
alone =0.125 mg/ml, MA/oxy1 combination - MA=0.125 mg/ml, oxy1= 0.0625 mg/ml, 






4.2.3 Experimental groups  
Animals were assigned to one of six experimental groups (N=8/grp). 1) 1 mg/kg MA (MA-
alone); 2)  0.5 mg/kg oxy (oxy1);  3) 1 mg/kg oxy (oxy2); 4) 1 mg/kg MA / 0.5 mg/kg oxy 
(MA/oxy1);  5) 1 mg/kg each of MA and oxy (MA/oxy2), and  6) saline. Behavioral tests 
(conditioned place preference (CPP), open field (OF), and novel object recognition (NOR)) were 
conducted over a three-week period (Table 1).  
 
4.2.4 Measures 
4.2.4.1 Conditioned Place Preference 
A 3-compartment conditioned place preference (CPP) apparatus (MED-CPP-MSAT; Med 
Associates, Vt., USA) was used. Each chamber consists of three distinct compartments separated 
by automatic metal guillotine doors. One compartment has black walls with a stainless steel rod 
floor, and the other has white walls with a stainless steel mesh floor. The central compartment is 
a neutral grey with a smooth PVC removable floor. A small amount of corncob bedding was 
placed in the trays underneath the floors in both cmpartments. To give an olfactory cue, a tea 
bag (caffeine-free Chamomile Tea, Trader Joe’s) was pl ced in the corncob bedding in the white 
compartment. During the experiments, the CPP apparatus was kept in an isolated quiet testing 
room. Photo-beam signals from the chambers were relayed to a desktop PC running MED-PC for 
Windows (Med Associates, Vt., USA). 
 Briefly, the CPP paradigm consisted of pre-condition ng (days 1-2), conditioning (days 3-
8), and post-conditioning phases (days 9-12). During all phases of CPP, mice were brought to the 
testing room 45 minutes prior to injection in order to habituate. For the pre-conditioning phase 





allowed 30 minutes of free exploration of all three chambers of the apparatus. The apparatus was 
cleaned between each mouse using 70% ethyl alcohol.  The time spent by the mouse in each 
compartment was recorded as the extent of baseline pref rence. An unbiased design was used to 
randomly assign animals to a drug-paired side of the apparatus. Drug conditioning spanned over 
6 days (days 3–8). Mice received a single injection of drug or saline before being restricted to the 
corresponding side of the apparatus for 30 minutes, with half of the animals receiving drug on 
the first day and half receiving saline. Drug and saline were injected on alternating days for a 
total of 3 pairings each. Post-conditioning spanned over four days (Days 9-12) during which 
animals received a saline injection and were placed in the central grey compartment and allowed 
30 minutes of free exploration of all three chambers. The difference in the percent of time spent 
in the drug paired vs. the saline paired compartmen b tween post-conditioning and pre-
conditioning represented the degree of conditioning induced by the drugs. Amount of activity in 
each compartment, defined by photobeam breaks, was also recorded during pre-conditioning, 
conditioning, and post-conditioning phases.  
 
4.2.4.2 Open Field 
The open field arena (43.2 cm x 43.2 cm x 30.5 cm) onsists of a white plastic base with clear 
plexiglass walls (ENV-515; Med Associates, Vt., USA).  The walls were covered with white 
paper. The arena was kept in a quiet isolated testing room. Illumination was provided by the 
room’s overhead lighting and was of equal intensity in all parts of the arena (~100 lux). Data was 





Behavior was automatically scored using the TopScan 2.0 program (Clever Sys Inc, Reston, 
VA). 
 The open field (OF) test consisted of a single 10 minute test on day 13. Mice were 
transported to the test room in their home cages 45 minutes prior to testing in order to habituate. 
Mice were then injected with drug and returned to the home cage for 30 minutes. Mice were then 
placed in the center of the arena and allowed to explore the apparatus for 10 minutes. The 
experimenter was not present in the room during testing. The arena was cleaned between tests 
using 70 % ethyl alcohol. The TopScan program was used to delineate areas within the arena; the 
center was defined as the inner 50% of the arena. The following behaviors were scored: time in 
center (s), time outside of center (s), distance in arena (mm), and velocity (mm/s). 
 
4.2.4.3 Novel Object Recognition 
The novel object recognition (NOR) paradigm was conducted according to the method of Denny 
et al. 2011. The test was performed in the same arena (ENV-515; Med Associates, Vt., USA) 
used for the open field test. Illumination and data collection were also identical to that used for 
the open field test. The NOR task was performed twice: on day 14 following acute injection of 
drug and on day 21 following injection of saline.  
Each NOR test used a set of three objects, which were available in duplicate. The first set 
of objects included  1) a blue plastic box (10 cm x 8.5 cm x 3cm); 2) a clear plastic funnel 
(diameter 7 cm, maximal height 13 cm); and 3) a grey cylindrical piece of pipe (diameter 5 cm, 
height 7.5 cm). The second set of objects included 1) a white and yellow pipette- tip box (12 cm 





cm); and 3) a white plastic Coplin staining jar with a round base/top (diameter 5.5cm) and a 
square body (3.5 cm x 3.5 cm, height 10 cm). The obj cts elicited equal levels of exploration in 
pilot experiments (data not shown). All animals were tested with both sets of objects. Half of the 
animals were tested with the first set of objects on day 14 following acute drug injection, and 
half on day 21 following saline injection. 
 The NOR procedure involved a total of five 5-minute exposures, with 3 minute intervals 
between each exposure (see Denny et al. 2012). First, mice were transported to the room in their 
home cages 45 minutes prior to testing in order to habituate. They were then weighed, injected 
with drug (day 14) or saline (day 21) and immediately placed in the center of the arena for the 
first exposure. The first four exposures served as habituation/learning sessions where two objects 
were placed symmetrically on either side of the aren  (~ 7cm from wall). During the 5th 
exposure, one of the two familiar objects was replaced by a  novel object (test session occurred at 
~ 29 min after injection). During the 3 minute inter- rial intervals, animals were returned to their 
home cage located in the testing room and the arena and objects were cleaned with 70% ethyl 
alcohol. The experimenter was not present in the room during testing. The novel object, the 
replaced familiar object, and the location of the novel object were counterbalanced across mice. 
The following behaviors were scored: sniffing within 1cm of object (s), distance in arena (mm), 
and velocity (mm/s). 
 
4.2.5 Statistical Analysis 
Data was analyzed using a 2x3 ANOVA in SAS for 1) CPP, 2) time in center for OF, 3) velocity 





included methamphetamine dose (0, 1 mg/kg) and oxycodone dose (0, 0.5, or 1 mg/kg). The 
interaction term was used to assess the effects of the drug combination. Linear mixed models 
were used to investigate 1) sensitization during CPP by comparing activity in the first and third 
drug exposure, 2) the persistence of conditioned place preference during 4 days of post-
conditioning tests and 3) acute vs. long-term memory effects within animals. 
 
4.3 Results 
4.3.1 Conditioned place preference 
Significant place preference was observed in all drug conditions when compared to saline (Fig. 
1a; largest p value = 0.005). Place preference was significantly influenced by oxycodone dose 
(F2,42=7.31, p=.002) and a significant interaction between methamphetamine and oxycodone 
(F2,42=4.87, p=.014). MA-alone produced a small but signif cant increase in place preference and 
oxycodone alone produced a dose-dependent response. The drug combination at both doses 
induced a place preference that was greater than MA-alone but less than oxy1 and oxy2 alone. 
However, these differences were not significant. When comparing the persistence of place 
preference over 4 days of post-conditioning tests (Fig. 1b), there were main effects of oxycodone 
dose, day, and a significant interaction between oxyc done and methamphetamine (smallest 
main effect, F3,111=3.44, p=.019). On day 2 of post-conditioning, all groups showed significantly 
elevated place preference compared to saline (MA: t111=-2.12, p=.036; oxy1: t111=-2.94, p=.004; 
MA/oxy1: t111=-2.37, p=.019; oxy2: t111=-3.81, p=.0002; MA/oxy2: t111=-2.86, p=.005). The 
place preference response on day 2 was similar to day 1, with both doses of the drug combination 





the oxy2 group showed significant place preference (t111=-3.75, p=.0003) and by day 4, place 
preference was not observed in any drug condition.  
 
4.3.2 Locomotor activity and Sensitization  
Locomotor activity was measured during the condition ng phase of the CPP procedure. 
Activity was significantly increased by MA but not xycodone.  Both doses of the drug 
combination produced an increase in activity at levels similar to MA-alone. To assess whether 
sensitization occurred, we compared the activity levels from the first and third drug exposure 
(Fig. 1c). Analysis revealed a significant main effect of methamphetamine and a significant 
interaction between methamphetamine and exposure number (smallest main effect,  F1,39=15.98, 
p=.0003).  Animals that received MA either alone or in combination showed an increase in 
activity from the first to the third drug exposure (MA-alone: t39=-2.2, p=.034; MA/oxy1: t39=-
2.55, p=.015; MA/oxy2: t39=-2.02, p=.05).  Sensitization was not observed in the oxy1 or oxy2 
groups. 
 
4.3.3 Open field 
State anxiety was quantified by the amount of time sp nt in the center of the open field arena, 
with greater time in the center indicating less anxiety. Analysis revealed a significant main effect 
of methamphetamine and oxycodone (smallest main effect, F2,46=3.57, p=.037), such that 
animals that received active drug spent less time in the center compared to those that received 





alone. In contrast, MAoxy2 produced significantly greater anxiety-like behavior than either drug 
alone.  
 
Figure 1. Bar histograms (A) display conditioned place prefer nce on the first day of post-
conditioning tests. * indicates significant difference from saline. The line graph (B) shows 
conditioned place preference over all four days of post-conditioning tests for each drug 
condition.  All drug conditions exhibited significant place preference during the first two days of 
post conditioning tests. By the fourth day, no animals exhibited place preference. Error bars were 
removed for clarity.  The line graph (C) displays sen itization data by showing the change in 
drug-induced locomotor activity from drug exposure 1 and 3. Animals that received MA alone or 








Locomotor activity in the open field was measured by velocity and distance travelled. 
Velocity was significantly increased by administration of active drug (smallest main effect, 
F2,46=28.28, p=.0001). Oxy1, oxy2, and MA-alone produced similar increases in velocity. Both 
drug combinations produced significantly greater velocity than either drug alone. . All drug 
conditions alsoproduced a dose-dependent increases in distance travelled (smallest main effect, 
F2, 46=25.15, p<.0001). Similar to the velocity data, both drug combinations produced 
significantly greater activity than each drug alone (largest p value for MA/oxy1 comparison, 
p=.003; MA/oxy2, p=.0001). Further, when comparing distance travelled in the center vs. 
periphery, distance in the center decreased with drug ose even as total distance increased 
(Fig2c).  
 
4.3.4 Novel Object Recognition 
Short-term memory was assessed during acute intoxication and one week later. There were no 
significant main effects of acute drug administration on the percent of time spent exploring the 
novel object (smallest main effect, F2,45=2.22, p=.12). However, similar to the activity data from 
open field, distance travelled was significantly affected by methamphetamine, oxycodone, and a 
significant interaction between the two (smallest main effect, F2,46=7.93, p=.001) .  
 There were also no significant main effects of drug treatment on memory one week later 
(smallest main effect, F2,44=2.18, p=.13). Mixed model analysis indicated that ere were no 
significant main effects of test (acute vs. one week later) or drug treatment  on novel object 







Figure 2. Bar histograms display anxiety-like behavior (A), velocity (B), and distance travelled 
(C) of mice in the open field paradigm. Letters indicate significant differences. All post hoc tests 







Figure 3. Bar histograms display the acute (A) and long-term (B) effects of drug administration 
on short-term memory measured by the novel object recognition paradigm. There were no 
significant acute or long-term effects of drug administration on this measure. 
 
4.4 Discussion 
The present results indicate that the reward value of MA and oxycodone were not altered 
when the drugs were administered together. Further, MA sensitization was not altered by the 
addition of oxycodone. There were no acute or long-term effects of either drug or their 
combination on short-term-memory. However, both doses of the drug combination produced 
significantly greater anxiety-like behavior compared to either drug alone. Similarly, both drug 
combinations significantly increased locomotor activity, measured by velocity and distance 
travelled, when compared to each drug alone. Importantly, these data provide the first empirical 
determination of the behavioral effects of the MA and oxy combination. The current data 





studying a new, popular stimulant-opioid combination. (Masukawa et al. 1993; Rowlett and 
Woolverton 1997; Ranaldi and Munn 1998; David et al. 2001; Rowlett et al. 2005; Martin et al. 
2006; Pereira et al. 2006; Rowlett et al. 2007; Lanet al. 2009). 
 
4.4.1 Reward 
As expected, both MA and oxycodone, when administered alone, produced significant 
increases in the ratio of time spent on the drug-paired side, interpreted as demonstrating drug-
induced reward. This is consistent with a sizable literature showing that amphetamines and 
opioids reliably produce conditioned-place preference in rodents (Wongwitdecha and Marsden 
1995; Suzuki et al. 1996; Tokuyama et al. 1996; Der-Avakian et al. 2007; Liu et al. 2009). To 
our surprise, however, the preference induced by MA was not altered by the addition of 
oxycodone. Our working hypothesis was that one reason for the popularity of stimulant-opioid 
combinations is because the combination enhances the rewarding effects compared to either drug 
alone. It is possible that the present range of MA-oxycodone doses examined were too narrow to 
observe enhancement of the rewarding effects of the drug combination. Other findings support 
this interpretation (Mello et al. 1995; Rowlett and Woolverton 1997; Duvauchelle et al. 1998; 
Gaiardi et al. 1998; Negus et al. 1998; Rowlett et al. 1998; Ward et al. 2005; Lan et al. 2009). 
For example, a report by Lan et al. 2009 compared place preference across 10 conditions that 
included three low doses of MA, morphine, and their combination. All drug conditions exhibited 
place preference, but a significant enhancement of CPP compared to each drug alone was 
observed at only one dose of the drug combination (MA: 0.75 mg/kg, morphine: 5 mg/kg). 





examined. Future studies should assess wider dose rang  and also investigate drug self-
administration to directly assess drug taking behavior. 
Mice that received methamphetamine exhibited sensitization; however, the addition of 
oxycodone did not alter the effect. Further, oxycodone alone did not induce sensitization at either 
of the doses tested. This data is congruent with previous studies utilizing similar doses of 
methamphetamine- (Jing et al. 2014) and oxycodone-alone (Niikura et al. 2013).   
 
4.4.2 Anxiety 
 We predicted that MA would increase anxiety-like behavior and that these effects would 
be offset when the drug was given in combination with oxycodone. This prediction was not 
borne out.  While MA increased anxiety-like behavior, the drug combination produced sub-
additive effects.  
 The current results are consistent with previous data indicating that MA is anxiogenic in 
open field and elevated plus maze measures of anxiety in rodents (Lapin 1993; Cancela et al. 
2001; Hayase et al. 2005). These results are also consistent with a few human studies 
demonstrating that a stress test or administration of stress hormones mildly increases the 
dysphoric effects of amphetamines while producing no alteration in positive subjective effects 
and dampening some stimulant-like effects (Wachtel et al. 2001; Wachtel and de Wit 2001; 
Harris et al. 2003; Soderpalm et al. 2003; Hearn et al. 2004). For example, Harris et al. 2003 
administered 50 mg hydrocortisone to MA-experienced subjects approximately 1.5 hours prior to 





effect” than those that received placebo hydrocortis ne, while ratings of “high” and “good drug 
effect” were unaltered (Harris et al. 2003). 
 Oxycodone was also moderately anxiogenic in the open field test. Specifically, the higher 
dose of oxycodone increased anxiety-like behavior. T  our knowledge, this is this first data 
investigating the effects of oxycodone on anxiety-like behavior. At first glance, the current 
results are surprising given the multitude of studies demonstrating that similar opioids, such as 
morphine, are anxiolytic (Rex et al. 1998; Koks et al. 1999; Shin et al. 2003; Glover and Davis 
2008; Rezayof et al. 2009). However, important pharmacological differences between 
oxycodone and other opiates may account for the obsrved anxiogenic effects. Unlike morphine, 
oxycodone acts on the kappa-opioid receptor in addition to the mu-opioid receptor, and it is 
postulated that oxycodone exerts some analgesic effe ts through this mechanism (Ross and 
Smith 1997; Nielsen et al. 2007). Accumulating evidnce suggests that kappa-opioid receptors 
are intrinsically involved in regulating the response to stress (for review, see Van't Veer and 
Carlezon 2013). In humans, selective kappa-opioid agonists produce negative mood states 
including dysphoria and anxiety (Pfeiffer et al. 1986).  Further, a number of animal studies have 
indicated that kappa-opioid antagonists reduce anxiety-like behavior caused by exposure to stress 
(McLaughlin et al. 2003; Knoll et al. 2007; Land et al. 2008; Wiley et al. 2009; Carr et al. 2010; 
Van't Veer et al. 2012). Indeed, kappa-opioid antagonists are currently undergoing Phase II 
clinical trials for the treatment of depression and xiety (Harrison 2013). Taken together, this 
data suggests that rather than reducing the negativ effects of the combined drugs, the MA/ 







4.4.3 Short-term memory 
4.4.3.1 Acute effects  
MA alone or in combination did not alter memory performance under the current 
conditions. We made no predictions about cognitive performance but were cognizant of the fact 
that drug-taking behavior is not only influenced by drug-related subjective effects but also by 
drug-induced performance effects. For example, data from laboratory studies of humans show 
that methamphetamine self-administration is enhanced under conditions that engender poor 
performance (Kirkpatrick et al. 2009). In addition, amphetamine misuse has dramatically 
increased among college students over the past decade (McCabe et al. 2006), presumably 
because of its performance-enhancing effects. However, the lack of observed performance 
effects on cognition is consistent with human data indicating that low doses of MA produces null 
effects or subtle increases in measures of memory (Weitzner 1965; Hurst et al. 1969; Rapoport et 
al. 1980; Kennedy et al. 1990; Soetens et al. 1993; Soetens et al. 1995; Mattay et al. 2000; 
Breitenstein et al. 2004; Whiting et al. 2007; Hart et al. 2008; Whiting et al. 2008; Zeeuws et al. 
2010; Kirkpatrick et al. 2012). This data is also consistent with human studies indicating that low 
doses of oxycodone produce null effects or subtle decreases in measures of memory (Zacny and 
Gutierrez 2003; Friswell et al. 2008; Cherrier et al. 2009; Schoedel et al. 2010). 
 
4.4.3.2 Long-term effects 
We also measured memory performance 7 days after the last drug injection. There were 
no long-term effects of MA, oxycodone, or the drug combination on short-term memory. The 





neurotoxic doses of MA on novel object recognition (Belcher et al. 2006; Belcher et al. 2008; 
Lee et al. 2011). These studies have produced mixed results, with some indicating null effects of 
MA and others showing impairment. For example, Belch r et al. 2006 utilized a sensitizing 
regimen of 3mg/kg MA injections every 2 days for a total of 10 injections. Animals that received 
MA showed significant memory disruptions one week after the last drug injection.  This data is 
incongruent with the present results, which also utilized a sensitizing dose of MA. However, in 
2008, Belcher et al. found that a 13-day escalating-dose plus binge MA regimen did not produce 
memory impairment (Belcher et al. 2008). Further studies will be needed to verify the cognitive 
effects of non-neurotoxic doses of MA in animal models. 
 
4.4.4 Limitations 
The present results should be interpreted within the context of several limitations. First, a single 
dose of methamphetamine was used in the current study. F ture studies should utilize a wider 
range of MA and oxycodone doses. Second, we observed that approximately half of the animals 
that received the largest MA/ oxycodone drug combinatio  did not interact with either object in 
the short-term memory task (Fig 3b). This may indicate that the larger dose of the drug 
combination produced a very strong effect that may h ve interfered with other behavioral 
measures as well. The current doses were chosen because they are near the threshold for 
inducing CPP. CPP has been induced with MA doses of 5 mg/kg and oxycodone up to 5 mg/kg 
(Tokuyama, Takashi, and Kaneto 1996; Suzuki, Kishimoto, and Misawa 1996, Wongwitdecha 
and Marsdem 1995; Liu et al. 2009; Der-Avakian et al. 2007). We propose that future studies 





produced by combining drugs. Finally, the observed increases in locomotor activity in the open-
field paradigm may have confounded the measure of anxiety-like behavior. However, we 
propose that this is unlikely because MA and both doses of oxycodone exhibited similar levels of 
increased activity, but differed in their effects on measures of anxiety-like behavior.  
 
4.4.5 Conclusions 
The current study importantly contributed the first empirical determination of the behavioral 
effects of the MA and oxycodone combination. Many behavioral effects of MA were unaltered 
by the addition of oxycodone. Specifically, CPP andsensitization were not increased by the drug 
combination, indicating that there is not an increased abuse liability. Locomotor activity and 
stress-induced anxiety-like behavior showed a sub-additive drug interaction. Further, there were 
no acute or long-term effects of the drug combination on short-term memory. Taken together, 
this data provides some evidence suggesting that the MA/ oxycodone drug combination 







Table 1: Study design and representative dosing schedule for MA-alone 
























MA= Methamphetamine (1 mg/kg)   Sal= Saline    
Pre-Cond= Pre-Conditioning day   OF= Open Field test   




















Chapter 5: General Discussion 
 
For the past 15 years, there has been considerable conc rn regarding the illicit use of 
marijuana, methamphetamine, and prescription pain relievers. However, several important gaps 
remain in our knowledge of these drugs. The current studies aim to address three of these gaps. 
 
5.1 Marijuana, substance use and misuse, and mental health among undergraduates 
 Young adults aged 18-25 represent the largest drug-using population in the United States. 
This age range also coincides with an important trasition from adolescence to adulthood, with 
young people experiencing greater freedoms and responsibilities. Unfortunately, this time in life 
also coincides with the onset of many mental health disorders, making this a particularly 
vulnerable population. However, there are considerabl  gaps in our understanding of the 
relationship between marijuana use, mental health, nd stress among young people. Study 1 
examined the relationship between frequency of marijuana use and other substance use, binge 
drinking, negative consequences associated with drinking, mental health problems, and stress. 
The results indicated that frequency of marijuana use was related to substance use, misuse, and 
depression and anxiety. Surprisingly, marijuana use was not related to stress. This data 
contributes to the field by indicating that marijuana use is indeed related to mental health within 
this population. This has important implications for university administrators and health 
professionals. Those wishing to prevent or treat substance use on campus should target efforts on 
students that present with mental health problems. Further, this is the first empirical data 
indicating that stress was not related to marijuana use. This is surprising, given that many young 
people report that they use drugs in order to help them cope with stress. It is possible that 
students commonly report drug use as stress-related coping because it is considered a socially 





in order to cope, and that these students are at the greatest risk for substance abuse and mental 
health problems.  
 
5.2 The acute effects of marijuana on cognitive performance during night shift work 
 Previous data indicates that several factors related to the person and environment in 
which a drug is taken can influence the acute effects. For example, regular marijuana smokers 
show widespread tolerance to the cognitive effects of marijuana. Further, data has indicated that 
the time of day of administration is an important modulator of drug effects. However, there have 
been few studies examining these effects in humans. Study 2 investigated the acute effects of 
marijuana during simulated night shift work in marijuana users. Results showed that smoked 
marijuana attenuated performance and mood during simulated night shift work. This data was 
surprising given that marijuana impairs performance during the day in well-rested individuals.  
This data furthers the database by indicating that marijuana has cognitive-enhancing effects 
under certain conditions. Additional research will be needed in order to determine whether these 
effects were caused by circadian modulation of the s imulant-related effects of marijuana, or by 
residual effects on improved sleep.  
 
5.3 Methamphetamine, oxycodone, and their combination 
 Finally, another important gap addressed by the present studies is the dearth of empirical 
information regarding the effects of methamphetamine when used in combination with 
oxycodone. Study 3 addressed this gap by beginning a systematic investigation of this 
combination utilizing a pre-clinical model with a wide range of cognitive and behavioral 





alone, although this was observed in a limited number of measures. As stimulant-opioid 
combinations are very popular among users, these data importantly provide the first empirical 
evidence of the effects of the methamphetamine-oxycodone combination.  
 
5.4 A translational approach to substance abuse and dependence 
 The present studies utilized a translational, multilevel approach in order to better 
understand substance use as a whole. A challenge in th scientific community, and particularly in 
research regarding substance use, is the limited communication between scientists using different 
approaches. In particular, there is a lack of scientif c discussion between pre-clinical and clinical 
researchers. This often results in the use of experimental measures that do not overlap and drug 
doses that do not translate well. For example, the u ilization of neurotoxic doses in animal 
studies of drug use have negatively skewed our understanding of drug effects. In this paradigm, 
drug-naïve animals are repeatedly administered suprathreshold doses of MA designed to induce 
overdose. Under these conditions, it would be surprising if the resulting brain damage did not 
have serious repercussions on cognitive function and behavior. While this may be a useful 
method of brain perturbation, it is problematic to extrapolate these results to human drug 
dependence. First, humans typically use slowly escalating doses, which has been shown to 
provide neural protection to the toxic effects of high dose (Riddle et al. 2002; Thomas et al. 
2005; O’Neil et al. 2006; Danacea et al. 2007). Secondly, accumulating evidence in humans 
suggests that long-term MA dependence does not cause severe brain damage resulting in 
cognitive deficits, but rather only subtly affects ognition in the long term (for review, see Hart 
et al. 2012). However, the pervasive view that MA is severely neurotoxic has been partially 





observed in rodent models that have no observable human equivalency have spawned elaborate 
theories used to explain human drug use.  
 Taken together, this has important implications for future studies. First, it is of paramount 
importance that the results of animal studies are not over-extrapolated and do not overshadow or 
influence the interpretation of results from human studies. Future studies using animal models 
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